

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 9/14, 9/72</p>	<p>A2</p>	<p>(11) International Publication Number: WO 98/16205 (43) International Publication Date: 23 April 1998 (23.04.98)</p>
<p>(21) International Application Number: PCT/US97/18901 (22) International Filing Date: 14 October 1997 (14.10.97) (30) Priority Data: 08/733,225 17 October 1996 (17.10.96) US (71) Applicant (for all designated States except US): INHALE THERAPEUTIC SYSTEMS [US/US]; 1060 East Meadow Circle, Palo Alto, CA 94303 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FOSTER, Linda, C. [US/US]; Apartment 31, 575 South Rengstorff Avenue, Mountain View, CA 94040 (US). KUO, Mei-chang [US/US]; 1823 Middlefield Road, Palo Alto, CA 949301 (US). BILLINGSLEY, Sheila, R. [US/US]; 665 Kirkland Drive #6, Sunnyvale, CA 94087 (US). (74) Agents: MORAN, Tom, M.; Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306-2155 (US) et al.</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: STABLE GLASSY STATE POWDER FORMULATIONS</p> <p>(57) Abstract</p> <p>A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10 °C (i.e. $T_g - T_s$ is greater than 10 °C). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions. A process for producing a powdered dispersible composition is also provided, wherein the process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the pharmacologically active material within the matrix.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

STABLE GLASSY STATE POWDER FORMULATIONS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of US Serial NO. 08/733,225 filed October 17, 1996, which in turn is a continuation-in-part of PCT Application No. PCT 96/05070, filed 12 April 1996, which is a continuation-in-part of U.S. Serial No. 08/423,515, filed 14 April 1995, which applications are incorporated herein by reference in their entirety.

BACKGROUND

Field of the invention

10 This invention relates to powdered pharmaceutical compositions that exhibit improved stability of dispersibility over time for inhalation therapy, to processes for preparing such compositions, and to methods for treating certain disease states using such compositions. The invention is based on the discovery that the dispersibility of a powdered pharmaceutical composition can be maintained over time if the composition is prepared in a glassy state. While it has been known that the chemical stability of a pharmaceutical may be maintained in the glassy state, this is the first recognition that a glassy state composition may be used to maintain dispersibility of a powdered composition over time.

20 Background of the invention

Over the years, certain drugs have been sold in compositions suitable for forming a drug dispersion for oral inhalation and consequent pulmonary absorption to treat various

conditions in humans. Such pulmonary drug delivery compositions are designed to be delivered by inhalation of a drug dispersion by the patient so that the active drug within the dispersion can reach the lung. It has been found that certain drugs delivered to the lung are readily absorbed through the alveolar region directly into blood circulation.

5 Thus, pulmonary delivery can be effective both for systemic delivery to treat various diseases and for localized delivery to treat diseases of the lungs.

Several approaches are used to deliver drugs via pulmonary absorption. These include liquid nebulizers, propellant-based metered dose inhalers (MDI's), and breath-actuated or air-assisted dry powder inhalers (DPI's). Aerosol dry powder inhalers
10 provide a particularly promising approach for pulmonary delivery of drugs. DPI's usually contain the powdered drug in a desiccated reservoir or blister pack. Inhaled or compressed air disperses the powder out of the device either directly into the patient's mouth (breath-actuated DPI) or into a holding chamber (air assisted DPI). (See e.g. U.S. Patent Application SN 08/423,568, filed 14 April 1995, which is incorporated herein by
15 reference). Propellant based MDIs may also employ a dry powdered drug which is suspended in a liquified gas propellant. To deliver the drug, the pressurized gas is abruptly released through a valve and in the resulting spray, the propellant evaporates almost immediately leaving a fine dry powder. Aerosol powders are useful for the delivery of various pharmaceutical products including small molecules, such as steroids;
20 peptides, such as hormone agonists; and proteins, such as insulin.

However, various disadvantages are evident with dry powder aerosol systems. If powder particles agglomerate to each other or adhere to the container or package walls over time, the concentration and thus the dosage of the delivered product will change. Furthermore, the powder particles may agglomerate and form hard cakes. With
25 propellant systems, valve clogging may occur if the powder agglomerates or the powder

concentration is too high. Additionally, powder may deposit on the valve seat and prevent the valve from closing properly. This leads to leakage of the propellant.

Agglomeration also reduces the amount of drug that can be deposited in the lung, since particles typically must be below about $5\mu\text{m}$ for deposition in the respiratory bronchioles and below about $2\mu\text{m}$ for deposition through the alveolar ducts and alveoli. As an aerosol dry powder is stored on the shelf over a period of time, agglomeration may become more pronounced. The accumulation of moisture in particular can accelerate the rate of agglomeration. This degradation of the solid state of the formulation over time makes it difficult to ensure delivery of a consistent and accurate dose of the drug active during the shelf life of the aerosol product. With aerosol powders, shelf life is dependent on both the chemical stability of the active drug and the physical stability of the solid state delivery system. When the active drug has good chemical stability, product shelf life is dictated more by the physical stability of the dosage form. When the active is a labile compound, such as the protein α -1 antitrypsin, the shelf life is dictated by both the chemical stability of the active drug in the dosage form and the physical stability of the dosage form itself. This has made the development of delivery systems for oral inhalation delivery of labile peptides and proteins particularly difficult. Additionally, since proteins and other macromolecules are poorly absorbed via other non-invasive routes of administration, pulmonary absorption is generally preferred.

The poor chemical stability of proteins in aqueous dosage forms is well known and solid dosage forms for proteins, i.e. dried proteins, are generally preferred. However, even in solid dosage forms, some proteins can be relatively unstable. This poor stability can be a product of both the method of preparing solid dosage forms, where the active drug is a protein, and of the storage environment around the protein within the dosage form.

A common method used to prepare relatively stable dry powders containing proteins is lyophilization (freeze-drying). However, lyophilization and further processing can force a protein to undergo significant chemical and physical changes. Processing events that may cause loss of activity include concentration of salts, precipitation, crystallization, chemical reactions, shear, pH, amount of residual moisture remaining after freeze-drying, and the like. Loss of activity is effected in part by physical changes to the tertiary structure of the protein, i.e. by unfolding.

Numerous solutions to the problem of protein stability in the dried form have been proposed in the literature. To optimize protein stability during lyophilization (process stability), for instance, the use of pH specific stabilizing ligands and non-specific stabilizing additives has been suggested. To stabilize the protein after lyophilization, it has been suggested that the excipients may form an amorphous glass with the protein. By supercooling a solution comprising a protein and excipients, freezing, wherein crystal habits can form, is bypassed and the solution forms a syrup followed by a viscoelastic rubber, and finally a glassy substance. The result is an amorphous solid, wherein the glassy excipient material, *e.g.* sucrose, is in an amorphous glassy form and encases the protein, thereby preventing any unfolding and slowing any molecular interactions or crossreactivity to a point of essential nonexistence, due to greatly reduced mobility of the protein and other molecules within the glassy composition. This process has been postulated to occur either via mechanical immobilization of the protein by the amorphous glass or via hydrogen bonding to polar and charged groups on the protein, i.e. via water replacement, thereby preventing drying induced denaturation and inhibiting further degradative interactions. As long as the glassy solid is stored at a temperature below its glass transition temperature and the residual moisture and, in some cases, oxygen

remaining in the dried product is relatively low, the labile protein can remain relatively stable.

However, maintaining chemical and biological activity of the active protein is only half of the challenge where the delivery system comprises a dry powder aerosol dosage form. As previously discussed, the solid state stability of the dosage form itself must be maintained over the shelf-life of the product. That is, the dispersibility over time of the aerosol powder must be maintained. The importance of consistent physical stability of the aerosol powder dosage form is made evident by the need to accurately deliver relatively low doses of highly active proteins and peptides that are efficacious within very narrow therapeutic ranges. The high cost of many proteins and peptides also makes it critical to ensure that a substantial portion of available active drug dispersed within a dosage form is delivered to the pulmonary epithelia. Furthermore, for proteins, peptides, and small molecule pharmaceutical formulation for pulmonary delivery via oral inhalation, the U.S. Food and Drug Administration (FDA) requires that a given drug delivery system deliver the active drug at a concentration consistently within 85-115% of the labeled dose for the active, i.e. a delivered dose $\pm 15\%$ of the labeled dose. While the prior art has at least in part addressed the problems of chemical and physical stability of active protein drugs, it has not adequately addressed the issue of solid state stability of an aerosol dry powder, i.e. dispersibility, for delivering proteins. Nor has the prior art addressed the solid state stability of amorphous dry powder inhalable formulations for delivery of small molecule or peptide drugs.

Thus, there is a need for a means to deliver drugs via pulmonary absorption that ensures physical stability of the solid state dosage form over time. That is, there is a need for an aerosol dry powder dosage form or similar dosage form that has a stable dispersibility over time.

Objects of the invention

It is an object of this invention to provide a pharmaceutical composition, particularly in a unit dosage form, for pulmonary administration that has stable dispersibility over time.

5 It is a further object of this invention to provide a process for manufacturing a pharmaceutical composition for pulmonary administration that has stable dispersibility over time.

A still further object of this invention is to provide a process for administering a pharmaceutical composition for pulmonary administration that has stable dispersibility
10 over time.

A still further object of this invention is to provide a novel drug delivery system that is capable of maintaining a stable level of dispersibility over time.

15 SUMMARY OF THE INVENTION

One aspect of this invention is a powdered, dispersible composition having stable dispersibility over time, a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10°C (i.e. $T_g - T_s$ is greater than 10°C), which composition comprises a
20 mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix.

Another aspect of this invention is a powdered dispersible composition in unit dosage form having stable dispersibility over time and a characteristic glass transition temperature (T_g), in combination with labelling instructions for treating pulmonary or
25 systemic disease in a mammalian subject that include a recommended storage temperature

(T_g), wherein the difference between T_g and T_s is at least about 10°C. The composition comprises a pharmaceutically acceptable glassy matrix and at least one pharmaceutically active material within the amorphous glassy matrix.

5 Still another aspect of this invention is a process for producing a powdered dispersible composition having stable dispersibility over time, a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_s) wherein the difference between T_g and T_s is at least about 10°C. The process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the
10 pharmacologically active material within the matrix.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a DSC thermogram of a freshly prepared formulation of Example 1 at a heating rate of 1°C per minute.

15 Figure 1B is a DSC thermogram of the same formulation shown in Figure 1A aged for two weeks under temperature cycling of 2°C to 37°C every 24 hours.

Figure 2 shows a DSC thermogram of an insulin composition of Example 2 at a heating rate of 1°C per minute.

20 Figure 3 shows a T_g moisture profile of a composition of this invention shown in Example 2.

Figure 4 shows a graph of the moisture sorption/desorption isotherm for a formulation of this invention shown in Example 2.

Figure 5 shows an X-ray diffraction pattern for a composition of this invention shown in Example 2.

Figure 6 shows a scanning electron microscope photograph of the particles of Example 2.

Figure 7 shows the effect of moisture on the T_g of a composition of Example 3.

Figure 8 shows a DER thermogram of the composition of this invention shown in
5 Example 11.

Figure 9A provides a cascade impactor particle size distribution for a composition of this invention shown in Example 11.

Figure 9B shows a cascade impactor particle size distribution of an aged composition of this invention.

10 Figure 10 shows a DER thermogram of the composition of Example 14.

Figure 11 shows a DSC thermogram of a composition of Example 15 at a heating rate of 1°C per minute.

Figure 12 is an X-ray diffraction pattern of a composition of Example 15.

Figure 13 shows a moisture sorption/desorption isotherm of a composition of
15 Example 15.

Figure 14 shows a DSC thermogram of a composition of Example 10 at a heating rate of 1°C per minute.

DETAILED DESCRIPTION OF PRESENTLY PREFERRED EMBODIMENTS

Definitions

The following definitions of terms are provided to help interpret the scope and breadth of the appended claims.

5

Delivered Dose: The phrase "delivered dose" as used herein refers to the percentage of the drug in a pharmaceutical dosage form employing an aerosol based delivery system that is delivered from the mouthpiece of the device. For example, a delivered dose of 70% indicates that 70% of the total amount of drug in the dosage form was delivered from the mouthpiece of the device.

10

Dispersibility: The term "dispersibility" means the degree to which a powder composition can be dispersed (i.e. suspended or aerosolized) in a current of air so that the dispersed particles can be respired or inhaled into the lungs of a subject. For example, a powder composition that is only 10% dispersible means that only 10% of the mass of finely-divided particles making up the composition can be suspended for oral inhalation into the lungs; 50% dispersibility means that 50% of the mass can be suspended. A standard measurement of dispersibility is described hereinafter.

15

Glass: The term "glass" or "glassy state" or "glassy matrix," as used herein, refers to a liquid that has lost its ability to flow, i.e. it is a liquid with a very high viscosity, wherein the viscosity ranges from 10^{10} to 10^{14} pascal-seconds. It can be viewed as a metastable amorphous system in which the molecules have vibrational motion and reduced rotational motion, but have very slow (almost immeasurable by today's techniques) translational motion when compared to the liquid state. As a metastable system, it is stable for long

20

25

periods of time when stored well below the glass transition temperature. Because glasses are not in a state of thermodynamic equilibrium, glasses stored at temperatures at or near the glass transition temperature relax to equilibrium upon storage and lose their high viscosity. The resultant rubbery or syrupy flowing liquid can lead to physical instability of the product. The process used to obtain a glassy matrix for the purposes of this invention is generally a solvent evaporation technique although other processes could produce a glassy matrix with acceptable T_g , for example, freeze drying followed by milling for micronization.

10 Glass Transition Temperature: The onset of the glass transition temperature is represented herein by the symbol T_g . The glass transition temperature is the temperature range at which a composition changes from a glassy or vitreous state to a syrup or rubbery state. Generally T_g is determined using differential scanning calorimetry (DSC) and is standardly taken as the temperature at which onset of the change of heat capacity (Cp) of the composition occurs upon scanning through the transition. The definition of T_g is always arbitrary and there is no present international convention. The T_g can be defined as the onset, midpoint or endpoint of the transition; for purposes of this invention we will use the onset of the changes in Cp when using DSC and DER. See the article entitled "Formation of Glasses from Liquids and Biopolymers" by C.A. Angell: Science, 15 267, 1924-1935 (31 MAR '95) and the article entitled "Differential Scanning Calorimetry Analysis of Glass Transitions" by Jan P. Wolanczyk: Cryo-Letters, 10, 73-76 (1989). For detailed mathematical treatment see "Nature of the Glass Transition and the Glassy State" by Gibbs and DiMarzio: Journal of Chemical Physics, 28, NO. 3, 373-383 (March, 1958). These articles are incorporated herein by reference.

MMAD: The abbreviation "MMAD" means mass median aerodynamic diameter. It refers to the particle size distribution of the particles of a dispersible powder when they are dispersed as an aerosol. The determination is generally made using a cascade impactor. For a discussion see Remington's Pharmaceutical Sciences, 18th Edition at pp. 1620-22.

MMD: The abbreviation MMD means mass median diameter. It refers to the particle size distribution of the bulk powder, as generally measured by centrifugal sedimentation techniques (*e.g.* The Horiba Particle Size Analyzer - Model CAPA700 is useful).

Powder: The term "powder" as used herein refers to a composition that consists of finely dispersed solid particles that are substantially free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli.

Recommended storage temperature: As used herein, the "recommended storage temperature" for a composition is the temperature (T_s) at which powdered drug composition is to be stored to maintain the stability of the drug product over the shelf life of the composition in order to ensure a consistently delivered dose. This temperature is initially determined by the manufacturer of the composition and approved by the governmental agency responsible for approval the composition for marketing (*e.g.* the Food and Drug Administration [FDA] in the U.S.). This temperature will vary for each approved drug product depending on the temperature sensitivity of the active drug and other materials in the product. The recommended storage temperature will vary from about 0° to about 40°C, but generally will be ambient temperature, i.e. about 25°C.

Usually a drug product will be kept at a temperature that is at or below the recommended storage temperature.

Composition of the Invention

5 As discussed previously, it is difficult to ensure consistent dispersibility over time, i.e. solid state stability, of dispersible powders. Inconsistent dispersibility of an aerosol powder over time leads to a number of undesirable consequences including inconsistent dosing of the drug active and inconsistent and insufficient delivery of a therapeutically effective amount of drug active. Thus, a dispersible powder that has stable dispersibility
10 over time is highly desirable.

 The present invention is based, at least in part, on the unexpected discovery that the dispersibility of a pharmaceutical powder for pulmonary administration can be maintained over time if the powder dosage form is prepared in a glassy state and the difference between the T_g and the T_s of the composition is greater than about 10°C and
15 preferably exceeds about 20°C. While not intending to be limited to a particular theory, it is believed that the dispersibility of a powder may in part be a result of the convoluted surfaces of powder particles that result when the particles are in an amorphous glassy state. The phenomenon of stability of dispersibility over time is a result of the glassy surface that appears to reduce the probability that individual particles will agglomerate
20 with each other upon storage. A particularly preferred embodiment of the present invention is one where at least the outermost regions, including the outer surface, of the powder particles are in an amorphous glassy state. It is thought that when the particles have a high T_g material in their surfaces (e.g. a protein typically exhibits a T_g above 100°C), the powder will be able to take up considerable amounts of moisture before
25 lowering the T_g to the point of instability ($T_g - T_s$ of less than about 10°C). Moreover,

proteins are desirable for the glassy surface of the particle because strong glasses are more resistant to temperature effects on viscosity even at temperatures above the T_g . Proteins are considered to be "strong" glasses, as compared to "fragile" glasses, as defined by C.A. Angell in the article mentioned above. See also article by C.A. Angell,
5 *J. Phys. Chem.* 98:137-80 (1994).

One aspect of the present invention is a powdered dispersible composition for pulmonary inhalation that exhibits stable dispersibility over time. The composition has a characteristic T_g and T_i , wherein the difference between T_g and T_i is at least about 10°C and preferably is more than about 20°C. The composition comprises a pharmaceutically-
10 acceptable, glassy matrix and at least one pharmacologically active material within the amorphous glassy matrix. Preferably, the composition will comprise a dispersible powder having particles where each dispersed particle exhibits at least an outer region having a glassy phase wherein the mean glass transition temperature is greater than about 35°C for ambient temperature storage of the powder. By ensuring the composition is substantially
15 in the glassy state, the solid state stability, i.e. dispersibility over time, of the dispersible powder, is significantly improved as compared to an amorphous or an amorphous/crystalline composition not in the glassy state.

Having stable dispersibility over time means that the dispersibility of the powdered composition of this invention when packaged as a unit dosage form (e.g. as a "blister
20 pack") does not appreciably change under normal storage conditions over the shelf life of the composition. The shelf life of a composition will vary based on a number of factors: the stability of the active material, the interaction of the active with the excipients, the expected storage conditions and the like. The shelf life may vary from a month to 3 years or more, but generally will be about six months to about 2 years. The
25 measurement of dispersibility is discussed in greater detail hereinafter. The term

dispersible is generally viewed as being synonymous with aerosolizable. Generally, the dispersibility is such that the delivered dose obtainable will be at least about 30%, usually at least about 40%, preferably at least about 50% and more preferably at least about 60%. To achieve such delivered dose, the composition of this invention is a powder with

5 the largest particle size less than about 10 microns (μm) in diameter with a shape that may be spheroidal or "raisin-like" with surface convolutions. The powdered composition of this invention will be composed of particles having a mass median diameter (MMD) of about $1\mu\text{m}$ to about $5\mu\text{m}$, usually about $1-4\mu\text{m}$ MMD, and preferably $1-3\mu\text{m}$ MMD. The aerosol particle size distribution is about $1-5\mu\text{m}$ mass median aerodynamic diameter

10 (MMAD), usually $1-4\mu\text{m}$ MMAD, and preferably $1-3\mu\text{m}$ MMAD. Preferably the composition exhibits less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w. Most preferably the composition will contain less than 2%w water. Less water is preferred because the T_g tends to decrease as more water is present. In general, a higher T_g value of the composition is preferred over a

15 lower T_g value. A higher value generally results in greater stability of the dispersibility over time. Preferably the composition exhibits a moisture uptake profile that allows absorption of up to about 5% moisture without a phase change from an amorphous to crystalline form or lowering of T_g to a point which makes the T_g-T_i less than about 10°C . Preferably T_g-T_i will be more than 20°C . However, it should be understood that the

20 hygroscopic compositions must be protected from significant moisture to be stable. Thus, hygroscopic compositions of this invention should be handled, packaged and stored under conditions that minimize direct contact with water after the compositions have been prepared. It should be noted, however, that glassy aerosol products are not necessarily hygroscopic.

Thus, in handling and packaging the powder, it is important to employ conditions that minimize the presence of water in the environment in which the operations take place. Generally by following the procedures taught in co-pending PCT/US97/04994 filed March 27, 1997 and PCT/IS9707779 filed May 7, 1997, one can minimize problems inherent in the presence of too much moisture. Both of these applications are incorporated herein by reference in their entirety.

Pharmacologically Active Materials

The active drug substances that are preferred are those used for administration via pulmonary inhalation. Such substances include non-macromolecule pharmaceuticals and macromolecule pharmaceuticals, including small molecules, peptides, glycoproteins, polysaccharides, proteoglycens, proteins, genes and gene vectors. The therapeutically effective amount (*i.e.* the amount needed to achieve the desired therapeutic effect) of the drug will vary in the composition depending on the biological activity of the drug employed and the amount needed in a unit dosage form. Because the compounds of the present invention are dispensable, it is highly preferred that they be manufactured in a unit dosage form in a manner that allows for ready manipulation by the formulator and by the consumer. Thus, the unit dosage will typically be between about 0.25 mg and 15 mg of total material in the dry powder composition, preferably between about 1 mg and 10 mg. Generally, the amount of active drug in the composition will vary from about 0.05%w to about 99.0%w. Most preferably the composition will be about 0.2% to about 97.0%w active drug.

The pharmacologically active materials useful for preparing the composition of this invention include any active drug administered to achieve the desired physiological effect when administered by inhalation, generally through pulmonary delivery. In the dry state,

the drug or phase of the composition containing the active drug may be in crystalline or amorphous form, depending in part on whether the active drug is a macromolecule such as a gene vector, protein, a peptide, or a polypeptide or is a non-macromolecule such as a salt or a small organic molecule. However, in all cases, the outer portion comprising the surface of the dosage form particle is preferably in a glassy form. It may be desirable to prepare the pharmacologically active material in a salt form that forms a glassy matrix itself, *e.g.* a citrate salt.

Active small molecules for systemic and local lung applications for use with the composition of the present invention are generally drugs of a non peptide nature and include, but are not limited to, steroids, including, but not limited to, estrogen, progesterone, testosterone, dexamethasone, triamcinolone, beclomethasone, beclomethasone dipropionate, fluocinolone, fluocinonide, flunisolide, flunisolide hemihydrate, triamcinolone acetamide, budesonide acetone, and the like; bronchodilators, including, but not limited to, adrenalin, isoproterenol, metaproterenol, terbutaline and its salts, isoetharine, albuterol and its salts, pirbuterol and its salts, bitolterate, ipratropium bromide, and the like; products and inhibitors of arachidonic acid metabolism such as analgesics, morphine, fentanyl, sumatriptan; mast cell inhibitors, such as cromolyn sodium, and the like; antibiotics, such as, pentamidine isethionate, and the like; alpha-blockers, retinoids such as retinoic acid; and the like.

Suitable macromolecules, *i.e.* peptides, polypeptides, proteins (including glycosylated and nonglycosylated proteins and cytokines) and gene vectors include, but are not limited to, calcitonin, erythropoietin (EPO), factor IX, factor VIII, 5-lipoxygenase and cyclooxygenase products and inhibitors, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), nerve growth factor (NGF), ciliary neurotrophic factor

(CNF), defensins, chemokines, growth hormone releasing factor (GRF), insulin-like growth factor (IGF-1), growth hormone, heparins (regular and low molecular weight), cyclosporin, insulin, leptin and its analogs and inhibitors interferon- α , interferon- β , interferon- γ , interleukins (e.g. interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-11, interleukin-12), interleukin-1 receptor antagonist, interleukin-1 receptor (IL-1R), luteinizing hormone releasing hormone (LHRH) agonists and antagonists, nafarelin, goserelin, leuprolide, endothelins, somatostatin analogs (e.g. octreotide), vasopressin analogs, amylin and analogs, insulinotropin, parathyroid hormone (PTH), peptide Y, gastrins, CCK peptides, thymosin- α -1, IIb/IIIa inhibitors, α -1 antitrypsin, anti-RSV antibody, cystic fibrosis transmembrane regulator (CFTR) gene, integrins, selectins, regulator (FTR) gene, deoxyribonuclease (DNase), FSH, bactericidal/permeability increasing protein (BPI), and antibodies such as anti-CMV antibody.

Useful active drug substances for use with the composition of the present invention for pulmonary administration also include appropriate gene vectors, such as nucleic acid complex, RNA or DNA sequences, that are used for gene therapy. In general, the nucleic acid complex is a DNA associated with an appropriate replication deficient recombinant virus that promotes transfection at the cellular level. Representative DNA plasmids include pCMV β , pCMV- β -gal (a CMV promoter linked to the E. coli Lac-Z gene, which codes for the enzyme β -galactosidase). Representative lipids that promote transfection include dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium (DMRIE), dioleoylphosphatidylethanolamine (DOPE), N-[1-(2,3-Dioleyloxy)Propyl]-N,N,N-trimethylammonium chloride (DOTMA), and the like. Such lipids may be used alone or in combination, for example, combinations of DOTMA with DOPE or DMRIE with

DOPE. Representative reapplication deficient transfection viruses include the adenovirus Ad2-CMV-LacZ-2.

Diseases to be Treated by the Compositions of this Invention

5 Systemic diseases that are suitable targets for treatment with pharmaceutical compounds designed for pulmonary administration, such as the compositions of the present invention, include, but are not limited to, osteoporosis prophylaxis and treatment, Paget's disease, hypercalcemia, anemia, hemophilia B, neutropenia, transplant failure, short stature, renal failure, blood clotting, type I and type II diabetes, hepatitis B and C, 10 multiple sclerosis, chronic granulomatous disease, renal cancer, prostate cancer, endometriosis, pain, ageing, obesity, gastrointestinal cancers, diabetes mellitus, diabetes insipidus, nocturnal enuresis, hypertension, amyotrophic lateral sclerosis (ALS), rheumatoid arthritis, cancer, immunodeficiency disease, acquired immune deficiency syndrome (AIDS), thrombocytopenia, fungal disease, anxiety, hypercholesterolemia, 15 peripheral neuropathies, refractory diarrheas, angina, cystic fibrosis, cytomegalovirus, Kaposi's sarcoma, hairy cell leukemia, migraines, hormone replacement therapy, lung transplants, and the like.

 Pulmonary diseases that are suitable targets for treatment with pharmaceutical compounds designed for pulmonary administration, such as the compositions of the 20 present invention, include, but are not limited to, respiratory syncytial virus, CMV, influenza and measles, chronic bronchitis, asthma, adult respiratory distress syndrome (ARDS), fungal disease, tuberculosis, emphysema, pneumocystis carini pneumonia, bronchospasm, hay fever, bronchial asthma, pulmonary hypertension, lung cancer treatment and prevention, pulmonary fibrosis, sarcoidosis, chronic obstructive pulmonary 25 disease (COPD) and the like.

In treating these conditions, a therapeutically effective amount of the active agent will be administered, i.e. an amount sufficient to obtain the desired curative, preventative or palliative effect. This amount is easily determined for each active agent by consulting such texts as Goodman and Gilman's "The Pharmacological Basis of Therapeutics,"

5 Eighth Edition (1993); The Physician's Desk Reference (1996); and The Merck Manual, Sixteenth Edition (1992).

The Glassy Matrix

The pharmaceutically acceptable matrix used for the composition of this invention
10 may be a drug active alone or may be a drug active in combination with a single pharmaceutically acceptable excipient or it may be a mixture of such excipients. The matrix will provide the composition with a characteristic T_g that may vary from about 35°C to about 200°C. Preferably the material will be chosen so that the T_g of the composition is at least about 45°C and more preferably at least about 55°C. The
15 pharmacologically active material may be in a crystalline or glassy state in the composition as long as the composition's measured T_g is such that the difference between T_g and T_m is at least about 10°C, preferably more than about 20°C and more preferably more than 30°C. Where the drug itself is not a good "glass former," an important aspect of the composition is to include an excipient that is a good "glass former" and is
20 pharmaceutically acceptable. For a glass former, the probability of germinating a crystal rather than forming a glassy solid during the preparation of the glassy matrix is so small that crystals simply tend not to form. While an excipient may be a good glass former, it may also have other characteristics useful for the composition. In addition to the glass former excipient, other additives may be included to aid in stability of the active, adjust

the pH (i.e. a buffering agent), improve dispersibility, aid in providing uniformity of delivery, and other purposes.

The combination of materials used in the composition of this invention will assist in providing stability of the drug dispersibility of the composition, consistency of the composition and uniform pulmonary delivery of the composition. The total amount of glass formers and additives needed will vary depending on the nature of the drug, i.e its structure, potency, activity, and the like. These excipients are generally chosen to be relatively free-flowing particulate solids, that do not thicken or polymerize upon contact with water, are toxicologically innocuous when inhaled as a dispersed powder and do not significantly interact with the active agent in a manner that adversely affects the desired physiological action of the drug. The amount of non-drug materials useful for preparing the composition of the present invention will serve to uniformly distribute the drug throughout the composition so that it can be uniformly dispersed when it is to be delivered into the lung. It will preferably also serve to dilute the active agent to a concentration at which the active agent can provide the desired beneficial palliative or curative results while at the same time minimizing any adverse side effects that might occur from too high a concentration. Thus, for an active drug that has a high physiological activity, more of the excipients will be employed. For an active agent that exhibits a lower physiological activity a lesser quantity of the excipients will be employed. The glass former may be used alone or in combination with the additives, which may be crystalline or amorphous.

While a number of pharmaceutically acceptable additives are acceptable for use with the composition of the present invention, the composition will generally be substantially free of any "penetration enhancers" which are undesirable for dosage forms intended for pulmonary absorption. Penetration enhancers are surface active compounds

which promote penetration of a drug through a mucosal membrane or lining and are proposed for use in intranasal, intrarectal, and intravaginal drug formulations. Types of penetration enhancers include, but are not limited to, bile salts, e.g., taurocholate, glycocholate, and deoxycholate; fusidates, e.g., taurodehydrofusidate; and biocompatible
5 detergents, e.g., tweens, Laureth-9, and the like. The use of penetration enhancers in formulations for the lungs is generally undesirable because the epithelial blood barrier in the lung can be adversely affected by such surface active compounds. The powder compositions of the present invention are readily absorbed in the lungs without the need to employ penetration enhancers.

10 Some additives that are useful as stabilizers for protein drugs such as the interferons include polypeptides of molecular weight of about 1,000 to about 100,000. Particularly valuable is human serum albumin (HSA), which not only stabilizes active protein drugs but also increases the dispersibility of a composition. See U.S. Patent Application Serial No. PCT/US96/05265 filed April 14, 1996, which is incorporated
15 herein by reference. Other stabilizers include certain carbohydrates such as monosaccharides, disaccharides and polysaccharides. These are believed to help protect the structure of the protein. Some of these materials may also act as bulking agents and glass formers, as discussed hereinafter.

Suitable additives for use with the composition of the present invention include,
20 but are not limited to, compatible carbohydrates, natural and synthetic polypeptides, amino acids, polymers, or combinations thereof. Suitable carbohydrates include monosaccharides, such as galactose, D-mannose, sorbose, dextrose, and the like. Monosaccharides will be present in small amounts to minimize the depression of the T_g . Disaccharides, such as lactose, trehalose, maltose, sucrose, and the like are also useful.
25 Other excipients include cyclodextrins, such as 2-hydroxypropyl- β -cyclodextrin; and

polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; and alditols, such as mannitol, xylitol, sorbitol, and the like. A preferred group of carbohydrates includes lactose, trehalose, raffinose, maltodextrins, and mannitol. Suitable polypeptides include the dipeptide aspartame. Suitable amino acids include any of the naturally occurring amino acids that form a powder under standard pharmaceutical processing techniques and include the non-polar (hydrophobic) amino acids and the polar (uncharged, positively charged and negatively charged) amino acids, such amino acids are of pharmaceutical grade and are generally regarded as safe (GRAS) by the FDA. Representative examples of non-polar amino acids include alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine. Representative examples of polar, uncharged amino acids include cysteine, glutamine, serine, threonine, and tyrosine. Representative examples of polar, positively charged amino acids include arginine, histidine, and lysine. Representative examples of negatively charged amino acids include aspartic acid and glutamic acid. Glycine is a preferred amino acid. Suitable synthetic organic polymers include poly[1-(2-oxo-1-pyrrolidinyl)ethylene, i.e. povidone or PVP.

Suitable pH adjusters or buffers include inorganic and organic acids, and bases and their salts. These include citric acid, sodium citrate, sodium gluconate, sodium ascorbate, and the like. Sodium citrate is preferred for pH of about 2-7 and sodium citrate/glycine for pH of about 7-9.

Glass formers suitable for use with the compositions of the present invention will generally be substances that will have a relatively high glass transition temperature (T_g), such that the T_g of the entire dosage form, i.e. the mean glass transition temperature, will be sufficiently high to remain above the temperatures to which the composition will be subjected during storage. The choice of a suitable glass former will greatly depend on the nature of the active drug. Preferable glass formers will have glass transition

temperatures that will yield compositions with mean glass transition temperatures above about 35°C and preferably above about 45°C. Thus, in the majority of cases, ratios of excipients required to accompany the active drug for any of the purposes previously mentioned will be identified first. Consequently, a suitable glass former will be chosen as well as the appropriate percentage of the composition it should comprise to obtain an acceptable glass transition temperature. In many cases the glass transition temperature of each of the excipients, active drug, and glass former will be known and a ratio of glass former to excipients can be relatively easily estimated and subsequently tested. The key is to produce a composition that will 1) be in a glassy state in at least the outer surface of a given particle of the aerosol powder and 2) have a T_g sufficiently above the T_i such that the composition will not likely be physically degraded and will instead retain a relatively stable morphological structure to ensure consistent dispersibility over time. Preferred unit dosage forms will have moisture uptake profiles that allow the glass to take up moisture over the shelf life of the product such that the $T_g - T_i$ does not fall below 10°C.

Glass formers suitable for use with the compositions of the present invention include certain materials that also are bulking agents. These are materials that are pharmaceutical grade and generally regarded as safe (GRAS) by the FDA. These include but are not limited to, carbohydrates, carbohydrate derivatives, carbohydrate polymers, synthetic organic polymers, organic carboxylic salts, proteins, polypeptides, peptides, and high molecular weight polysaccharides. While carbohydrates such as monosaccharides (*e.g.* galactose, D-mannose, sorbose, dextrose and the like) are useful in small amounts as additives and may act to stabilize the conformation of large proteins, they are generally not good glass formers. Their T_g values are too low, often less than about 25°C. In general, T_g is a function of molecular weight, with higher molecular weight materials having a higher T_g . However, once the molecular weight of a glass former goes above

about 3000, the T_g does not appear to increase at the same rate, if at all. Some excipients may not be good glass formers alone, but may be useful when combined with other excipients that tend to keep the combination in the glassy state. For example, mannitol alone is not a good glass former, but when combined with glycine (*e.g.* about a 1:1 w/w ratio) the combination may be useful as a glass former. Suitable carbohydrates, carbohydrate polymers and carbohydrate derivatives include, but are not limited to, compounds that generally have at least 11 carbons or more with a molecular weight of up to about 100,000 or more. Examples include disaccharides, such as lactose, trehalose, maltose, sucrose, and the like; polysaccharides, such as raffinose, maltotriose, stachyose, maltodextrins, hydroxyethyl starch, dextrans, and the like; glucopyranosyl-alditols, such as glucopyranosyl-mannitol, glucopyranosyl-sorbitol, and the like. Very high molecular weight polysaccharides having a modified structure are also useful. These excipients include heparin (a sulfated polysaccharide) and hyaluronic acid (a muco-polysaccharide). A preferred group of carbohydrates includes lactose, raffinose, trehalose, maltodextrin, sucrose, maltose, stachyose, polydextrose, cyclodextrin, glucopyranosyl-mannitol, hydroxyethyl starch and glucopyranosyl-sorbitol. Particularly useful glass formers include the salts of organic acids such as lactic acid, ascorbic acid, maleic acid, oxalic acid, malonic acid, malic acid, succinic acid, citric acid, gluconic acid, glutamic acid, and the like. Generally anions with high basicity are preferred. Multivalent anions tend to form glasses with a higher T_g than monovalent anions. Salts may include cations such as sodium, potassium, calcium, magnesium, and the like. Examples include sodium citrate, sodium lactate, sodium maleate, magnesium gluconate, sodium ascorbate, and the like. Sodium salts are preferred over potassium salts. Divalent cations form glasses more readily. The preferred salt will have a high T_g and sufficient solubility to inhibit

crystallization and thereby form the glassy matrix. In some cases mixtures of cations may be useful (e.g. calcium and sodium salts).

Other useful glass formers include proteins and polypeptides. These include HSA, polyamino acids (*e.g.* polyalanine, polyarginine, polyglycine, polyglutamic acid and the like), casein, collagen, gelatin, and some pharmacologically active compounds (*e.g.* insulin). In some cases (*e.g.* insulin) the active itself is a glass former and assists in forming the glassy matrix. Other suitable glass forming excipients include hydroxypropyl- β -cyclodextrin (HP- β -CD), albumin, povidone, pectin, Ficoll® polymer (see U.S. Patent 3,300,474 which is incorporated herein by reference), and the like. The most preferable glass formers are sodium citrate, sodium tartrate, trehalose, povidone, sucrose, lactose, maltodextrin, and raffinose. Ideally, compounds that are GRAS compounds are preferred over those that are not GRAS. However, particularly suitable non-GRAS compounds should not be eliminated if they can become GRAS compounds in the future.

It should be noted that although a preferred glass former may already be part of the formulation for other purposes, it may not be of the proper percentage to provide the desired characteristics of the present invention to stabilize the solid state dispersibility over time of the composition. The determination of the proper amount of glass former should be made after the initial formulation is chosen. For example, raffinose can be used to enhance the chemical stability of a labile protein while being dried or stored, such as Il-1 Receptor, in a formulation. Raffinose may also be preferred to comprise the glass former to obtain the added benefit of stabilizing dispersibility over time. However, the amount required for stabilizing dispersibility may differ significantly from the amount required to enhance the chemical stability of the protein active drug. Alternatively, it can be the case that a combination of raffinose with another glass former, such as sodium

citrate, is more preferred to comprise the composition, wherein only raffinose is needed to enhance the chemical stability of the labile protein active drug. Additionally, it may be advisable to change the stabilizer previously used for a given formulation where the added benefit of stabilizing dispersibility over time is desired. If the preferred glass former can
5 also suitably enhance the chemical stability of the labile protein active drug, it could simplify and minimize the expense of formulation to use the same carbohydrate, for instance, to both enhance the chemical stability of the labile protein and provide dispersibility stabilization, wherein the concentration of carbohydrate chosen is suitable for both functions. Of course, for small molecules, no stabilizer for the drug active is
10 typically required, thus the choice of a glass former is more straight forward.

In one preferred embodiment of the present invention, a protein active drug, such as insulin, is combined and spray dried with a suitable protein stabilizing additive, such as mannitol; and a glass forming buffer, such as sodium citrate; and of glycine. As previously discussed, the choice of components of an aerosol powder formulation depends
15 on the nature of the active drug. In the case of a protein, its chemical and physical stability is critical as well as its dispersibility within the dosage form. In the case of a preferred embodiment of the present invention the protein will be spray dried rather than lyophilized. Thus, the stability of the protein during the spray drying process is not as tenuous as during a lyophilization process. Once in the dosage form, the chemical and
20 physical stability of the protein can be maintained by using methods and excipients well known in the art and previously mentioned.

Dispersibility itself can be enhanced by a number of methods, including the use of bulking agents. Human serum albumin for instance has been found to be an excellent dispersibility enhancer in addition to acting as glass formers to stabilize dispersibility over
25 time.

Selection of the glass former to maintain a stable dispersibility over time will depend on the nature of the composition described above. A glass former will be chosen that will yield a glass transition temperature of the entire composition sufficiently high to ensure that the highest temperature for the labeled storage conditions for the composition is essentially below the glass transition temperature, i.e. about 10°C less. The lower a composition is below its glass transition temperature, the more stable it is. The glass transition temperature of a composition will depend on the nature of the glass former, other excipients, the active drug and on the amount of residual moisture or solvent in the composition. Generally, the presence of moisture within the composition will decrease its glass transition temperature. Additionally, a composition will typically absorb some moisture over time. Thus, glass formers indicated above as preferred have glass transition temperatures that are sufficiently high for most formulations.

Another aspect of this invention is the combination of the powdered composition of this invention with a pharmaceutically-acceptable carrier having a particle size that is not respirable, i.e. is of such a size that it will not be taken into the lungs in any significant amount. This can be viewed as a uniform blend of smaller particles of the glassy matrix (e.g., less than 10 μm , preferably between 1-5 μm MMD and MMAD) with larger particles of the carrier (e.g., about 15-100 μm , preferably about 25-27 μm). Such a blend improves the flow characteristics of the blend in filling the blister packs of a unit dosage form. Upon dispersion, the smaller particles are then respired into the lungs while the larger particles are generally retained in the mouth. Carriers suitable for blending include crystalline or amorphous glassy excipients that have an acceptable taste and are toxicologically innocuous, whether inhaled or taken orally. Crystalline carriers are preferred and include, e.g., the saccharides, disaccharides, and polysaccharides. Representative examples include lactose, mannitol, sucrose, xylitol and the like.

Table I lists glass transition temperatures for suitable glass formers and preferred glass formers. These values were primarily obtained from Franks et al "Materials Science and the Production of Shelf-Stable Biologicals" Pharmaceutical Technology, March 1992, 32-50 and may vary somewhat from other values in the literature depending on moisture content.

Glass Former	Glass Transition Temperature °C
Sucrose	56
Polydextrose	56
Glucopyranosyl-mannitol	57
Glucopyranosyl-sorbitol	60
Maltotriose	76
Cellobiose	77
Trehalose	77
Dextran	83
Raffinose	90
Sodium Citrate	106

In preparing the compositions of this invention, the pharmacologically active material will be present in an amount that will range between about 0.05%w for a drug that is very active to about 99%w for a drug that is not very active and is a glass former itself. Generally, the range of active drug will be from about 0.2%w to about 97.0%w, preferably about 0.5%w to about 90%w. The remainder of the composition may comprise an excipient glass former with additives included as needed. For most compositions, additives will be present in the matrix at a level of less than about 20%w.

Determining T_g

Preferably, T_g for a composition is determined using differential scanning calorimetry (DSC). As discussed hereinbefore, in using DSC techniques the onset, midpoint or endpoint of the change in C_p can be used, as long as the technique uses the point consistently. In the DSC measurements in this application, the onset of the change in specific heat, C_p , is the reported glass transition temperature. The theory and practice of thermal analysis such as DSC techniques useful for measuring T_g are known in the art and can be found in the book entitled "Thermal Analysis" by Bernard Wunderlich, Academic Press, 1990, which is incorporated herein by reference. Adjustments may be made to reflect the conditions and equipment of a particular facility.

Another technique for determining T_g is thermal mechanical analysis (TMA), which measures expansion or contraction of a solid on warming or cooling. This is a less expensive technique but less valuable for powder compositions due to compaction problems with powders.

A third technique for determining T_g is dielectric relaxation (DER) analysis. The glass transition using DER is represented by a step change in the permittivity of the sample. Glass transitions are easily identified in a DER heating scan because those transitions show a change in onset temperature (reported at T_g) with frequency whereas first order transitions do not. For the examples of this invention using DER, a frequency of 1 Hertz (Hz) was used. Generally, this technique is particularly useful for protein-based glassy matrixes. DER analysis is described in the books entitled "Disorder Effects of Relaxational Processes, Glass, Polymer, Proteins" by R. Richert and A. Blumen, 1994; "Dielectric and Electronic Properties of Biological Materials" by R. Pethig, 1979; and "Dielectric Analysis of Pharmaceutical Systems," by Duncan Q.M. Craig, Taylor and Francis, 1995, which are incorporated herein by reference.

Composition In Combination With Labeling Instructions

Another aspect of this invention is a unit dosage form powdered aerosol composition having stable dispersibility over time in combination with labelling instructions for treating pulmonary or systemic disease in a mammalian subject. The composition exhibits a characteristic T_g and a storage temperature (T_s) that is recommended in its approved labelling, with the difference between T_g and T_s being at least 10°C. As discussed herein, the composition is a pharmacologically active material within a glassy matrix. As previously mentioned, the FDA requires that a drug product be delivered to a site of action in an amount within a suitable range of its indicated delivered dose. This suitable range is characterized by a delivered dose of 85%-115% of the labeled dose. Dosage forms prepared with the compositions of the present invention will usually provide a formulation that complies with these FDA requirements. More importantly the compositions of the present invention will provide for a dosage form that maintains dispersibility longer and thus has a longer shelf life. This is a key aspect of the invention in that before a compound can be approved for any particular use, it must be approved for marketing by the FDA. Part of that process includes providing a label, as defined in 21 Code of Federal Regulations (CFR) §201, that will accompany the pharmaceutical composition which is ultimately sold. While the label will include a definition of the composition and other items, such as the clinical pharmacology, mechanism of action, drug resistance, pharmacokinetics, absorption, bioavailability, contraindications, and the like, it will also generally provide the necessary dosage, administration, usage and storage temperature. For example, 21 CFR § 341.76(c)(2) provides that labeling of bronchodilator drug products for pulmonary inhalation via a pressurized metered-dose aerosol container be labeled to indicate that each inhalation (dose) contain the equivalent of 0.16 to 0.25 mg of epinephrine. In order for this

requirement to be met, the drug must be able to be sufficiently dispersed in the formulation and the stability of dispersibility over time must be maintained so as to consistently deliver a dose within the range specified above. Thus, the combination of the drug with appropriate labelling instructions is important for proper usage of the drug once it gets to the market.

Process For Preparing Compositions Of The Invention

Another aspect of this invention is a process for producing a powdered dispersible composition having stable dispersibility over time by removing the solvent from a solution of the composition under conditions sufficient to maintain the composition in an amorphous form until sufficient solvent is removed to form a glassy state.

In preparing the composition of this invention conditions and materials are used that provide a composition that exhibits a T_g that is at least about 10°C greater than the recommended storage temperatures (T_s). Usually this storage temperature is at ambient temperature of about 25°C. To have a difference between T_g and T_s of 10°C, the T_g is about 35°C. For a difference of about 20°C greater than ambient, T_g is about 45°C and for a difference of at least about 30°C, the T_g is about 55°C. The compositions preferably have higher T_g values to better maintain dispersibility over time under adverse conditions such as higher temperatures and greater relative humidity (RH). Preferably, processing techniques provide a powder composition having particles with a material (e.g., a protein) on the surface showing a particularly high T_g . Having particles with the majority of glassy state material on the surface is important for at least two reasons: (1) this provides a composition with a higher T_g that allows for a larger amount of water to be added without reducing the T_g below the desired level and (2) this provides greater

resistance to viscosity changes with increased temperature. This results in a composition that maintains its dispersibility over time in spite of high RH or temperature swings.

In general, the solvent removal process techniques that are useful include spray drying; lyophilization followed by milling to micronize the powder; atomization onto a cold surface, followed by sublimation and collection of the micronized powder; evaporative drying of a non-frozen solution in a vacuum oven or centrifugal evaporator maintained at temperatures where the solution does not freeze (5 to 50°C), followed by milling; atomization of a chilled or non-chilled aqueous drug solution into an organic suspending medium containing a solubilized protein, whereafter the organic medium is evaporated and the powder milled to respirable particle size. The resultant powder particles are glassy or crystalline internally with a majority of the glassy matrix coating on the surface. Similarly, cosolvent precipitation techniques and evaporation/milling may be used to produce similar particles.

The preferred method for preparing a dispersible powdered composition of this invention comprises spray drying a homogenous aqueous mixture comprising water, with or without an organic solvent; a glass forming excipient, and an active agent suitable for treating a disease state by inhalation under conditions sufficient to provide a dispersible powdered pharmaceutical composition having a particle size less than about ten microns with the MMD and MMAD range discussed herein.

The spray drying method generally consists of bringing together a highly dispersed liquid, which is the aqueous composition defined above, and a sufficient volume of hot air to produce evaporation and drying of the liquid droplets. The feed liquid may be a solution, colloidal suspension or emulsion provided the feed is capable of being atomized. Preferably a solution is employed. In general the feed is sprayed into a current of warm filtered air that evaporates the water and conveys the dried product to a collector. The

spent air is then exhausted with the moisture. While, in general, the resulting spray-dried powdered particles are homogenous, approximately spheroidal in shape and nearly uniform in size, the improvement of this invention results in particles that are comprised of a glassy matrix and are irregular in shape. A further discussion of spray drying can be found in Chapter 89 of *Remington's* at pages 1646-47. It is found that the process of this invention works particularly well using a Buchi Model 190 or Niro Mobile Minor spray dryer, modified to operate at high air flow rates. Generally, the inlet temperature and the outlet temperature are not critical but will be of such a level to result in a composition having the desired T_g . The inlet temperature, solution composition of the formulation, and feed rate are parameters which are adjusted to achieve a given outlet temperature (which results in a powder with the desired moisture content). Atomization air flow, solution composition of the formulation, and feed rate are adjusted to achieve the desired particle size. The spray dryer inlet temperatures thus may be between temperatures of about 80°C to about 200°C, with the outlet temperature being at temperatures of about 50°C to 100°C. Preferably, these temperatures will be from 90°C to 180°C for inlet and from 50°C to 90°C for outlet. The powder processing conditions are adjusted as described above for both scales of production (e.g. the feed flow rate for the Buchi was 3 to 6mL/minute and about 10-fold that flow rate for the Niro batch scale and atomizer air flow rate was 700-800 LPH (liters per hour) for the Buchi and 12 scfm at 43-47 psig for the Niro). The particle size may be further adjusted by adjusting the pressure drop between the cyclone inlet and cyclone outlet. This is done by adjusting the size of the openings in accordance with standard engineering guidelines. Secondary drying or vacuum drying may be employed, but is not needed.


By following the general process teachings above, one obtains a composition having the desired particle size, T_g , and dispersibility characteristics to be respirable and suitable for pulmonary delivery to a subject in need thereof.

5 Dispersibility Determination

To determine the dispersibility of a composition of this invention as compared to other compositions, one can use a standard test for quantifying the deliverable dose of a unit dosage form by aerosolizing a powder composition, collecting the aerosolized composition and measuring the delivered material using the equipment and procedure as
10 described hereinafter.

A high level of dispersibility leads to a high percentage of delivered dose of a composition of this invention. Delivered dose is a key parameter in the success of a powdered composition. It is a measure of the efficiency by which a composition is delivered by a dry powder pulmonary inhaler device to (1) extract the test powder from a
15 dosage receptacle such as a blister package, (2) aerosolize that powder into a "standing cloud" of fine particles in an aerosol chamber, (3) deliver those fine particles through the mouthpiece of the device during a test inhalation. The dose delivered with each formulation tested is generally determined as follows. A single blister pack, filled with approximately 5 mg of powder, is loaded into the device. The device is actuated,
20 suspending the powder into the device's aerosol chamber. The "standing cloud" of fine particles is then drawn from the chamber at an airflow rate of 30L/min for 2.5 seconds (1.25 L inspired volume) and the sample collected on a suitable filter, a polyvinylidene fluoride membrane filter with a 0.65 μm pore size is particularly useful. The sampling airflow pattern is controlled by an automatic timer and operated to simulate a patient's
25 slow deep inspiration. The overall efficiency (delivered dose) and percent of the powder

left in the blister pack after actuation is determined gravimetrically by weighing the powder on the filter and the amount of powder left in the blister pack. This process may be visualized as follows:



10

The calculation of dispersibility is as follows:

1. Total mass of powdered composition in a unit dosage (*e.g.*, a 5 mg blister pack).
2. Total mass of powdered composition aerosolized in a unit dosage and
15 collected on the filter (*e.g.*, 2.5 mg)
3. Dispersibility is defined as the mass of powder collected on the filter
 divided by the mass of powder in the blister expressed as a percent. (*e.g.*,
 $2.5 \div 5 = 50\%$). The relative standard deviation (RSD) is calculated by
 dividing the standard deviation by the mean and multiplying by 100.

20

Equipment that is suitable (with minor modifications) for use in determining dispersibility is described in PCT application published as International Patent Number WO 93/00951, published 21 January 1993 entitled Method and Device For Aerosolized Medicaments by John S. Patton. That application in its entirety is incorporated herein by reference.

25

Particle Size Determination

Particle size can be measured by any one of various methods known to those of ordinary skill in the art. For example, particle size distribution of the bulk powder is measured by liquid centrifugal sedimentation in a particle size analyzer. Particle size can also be characterized using a scanning electron microscope (SEM). By using SEM, the surface morphology can also be examined. However, only a few particles can be examined by SEM requiring other methods to be used to quantitatively determine particle size distribution.

The particle size distribution of the aerosol was obtained using a 6-stage (16, 8, 4, 2, 1, 0.5 μ m cut sizes) cascade impactor (California Measurements, Sierra Madre, CA) or an 8-stage (9.0, 5.8, 4.7, 3.3, 2.1, 1.1, 0.7, 0.4 μ m cut sizes) cascade impactor (Graseby Andersen, Smyrna, GA). For each measurement, one to 5 blister packs filled with approximately 5 mg of powder was dispersed from the inhaler (5 to 15 mg total powder for the California Measurements impactor and 15 to 25 mg total powder for the Andersen). The resultant aerosol was drawn from the inhaler chamber into the cascade impactor, with airflow rates set to 12.5 L/minute or 28.3 L/minute respectively for the California Measurements and Graseby Andersen impactors. The particle size distribution was determined by weighing the powder on the impactor plates and evaluating the results on a log-probability plot. Both the mass median aerodynamic (MMAD) and mass fraction less than 5 μ m were determined from the log-probability plot.

EXAMPLES

Example 1

This example describes a 20% insulin formulation for which the difference
5 between T_g and T_i is less than 10°C. This resulted in a formulation that, although
chemically stable, did not have stable dispersibility over the desired shelf life of the
product at standard recommended storage temperature (T_s) testing conditions.

A 20% insulin aerosol formulation was obtained by preparing a solution of human
zinc insulin, mannitol, sodium citrate dihydrate, and citric acid monohydrate. Bulk
10 crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN.,
and U.S.P. grade excipients were used. The solution contained 1.5 mg insulin, 4.96 mg
mannitol, 1.04 mg citrate buffer (sodium citrate and citric acid) per milliliter of deionized
water for a total solids concentration of 7.5 mg/mL at pH 6.7. A dry powder was
prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer -
15 Model 190 under the following conditions:

	Temperature of aqueous solution	2-8°C
	Inlet temperature	123°C
	Outlet temperature	81°C
20	Feed rate	5.3 mL/min
	Jacketed cyclone temperature	30°C

After all the aqueous solution was pumped into the spray dryer, the outlet
temperature was maintained at 85°C for 10 minutes by slowly decreasing the inlet
25 temperature to provide a secondary drying.

The resultant dry powder aerosol formulation contained the following solids content: 20.0 % insulin, 66.2 % mannitol, 13.1 % sodium citrate, 0.7% citric acid

Characterization and Stability:

5 Insulin powders were packaged in foil pouch barrier packaging with desiccant. The pouches were stored at 30°C, 40°C, and at temperature cycling conditions of 2 to 37°C every 24 hours. Stability samples were evaluated for insulin content and purity using reversed phase HPLC, moisture content, aerosol performance based on delivered dose of insulin, and glass transition temperature using differential scanning calorimetry.

10 Reversed phase HPLC analysis using a stability-indicating method for insulin showed no changes in the insulin content or purity at any of the storage conditions tested. After storage, the insulin content accounted for 99% of the expected insulin. For one batch of the citrate/mannitol powder stored for 22 months at ambient room temperature, the insulin purity was 99% initial with trace amounts of degradation products appearing in
15 the chromatogram.

Moisture content was measured by a coulometric Karl Fisher method using a Mitsubishi CA-06 Moisture Meter. Dry powder aerosols prepared using these process conditions resulted in compositions containing 0.5% to 1.5% moisture.

20 Thermal analysis using differential scanning calorimetry (DSC) was carried out using a Seiko calorimeter calibrated using nitrogen purge gas and indium as a standard reference. Powder samples (10-20 mg) were hermetically sealed in aluminum pans, cooled to < -50°C and then heated at 1°C per minute. Thermograms were generated as the samples were heated. The glass transition temperatures of freshly prepared powder formulations were in the range of 28 to 34°C (at 0.4 to 1.4% moisture). X-ray
25 diffraction and microscopic analysis showed that the powders were partially crystalline

and a melting endotherm for mannitol was observed at about 150°C by DSC. More importantly, DSC analysis showed a loss of the glassy state for these powders after storage for a few weeks at 30°C, 40°C, or with temperature cycling from 2 to 37°C. Thermograms of the initial and aged formulation are shown in Figures 1A and 1B. In the thermogram of the initial sample (Figure 1A), a glass transition temperature with onset of about 32°C is observed, followed by an enthalpic relaxation of the glass at 33°C. In contrast (Figure 1B), the powder aged for 2 weeks under temperature cycling from 2-37°C showed a broad endotherm at 41°C, i.e. the loss of glass transition. Similar results were obtained at all storage conditions.

The delivered dose of the insulin powder compositions was measured by collecting the aerosol powder produced by a dry powder dispersion device on a filter placed over the device mouth piece. This measurement is similar to devices described in U.S. Patent No. 5,458,135 and Application Serial Numbers PCT/US95/11655 and PCT/US92/05621, the disclosures of which are incorporated herein by reference. The delivered dose of the insulin powder composition was determined as the mass percentage of the total powder (5.0 mg) loaded into the device. Aerosol and DSC data are presented below. Aerosol delivered dose for these powder compositions decreased significantly upon storage. Concurrent DSC analysis showed that the initial glassy powders quickly (< 1 month) converted to a non-glassy state.

Composition Code	Insulin Content	Storage Condition	Delivered Dose (%)	Moisture Content (%)	T _g by DSC
-001 (lot # R156-15A)	20.0	initial	70.6 ± 4.0	1.0	28
		2 week; cycling 2-37°C	56.7 ± 2.9	0.7	
		4 week; 30°C	51.2 ± 12.5	0.5	none
		4 week; 40°C	35.9 ± 9.1	1.4	none
		12 week; 30°C	45.1 ± 5.4	0.5	
I-001 (lot # R95008)	20.0	initial	72.4 ± 1.5	0.4	32
		2 week; cycling 2-37°C	62.9 ± 2.6	0.5	32
		4 week; 30°C	69.3 ± 1.8	0.7	not done
		8 week; 30°C	68.7 ± 3.0	0.7	32
		4 week; 40°C	49.7 ± 3.0	not done	none

Example 2

This example sets forth a 20% insulin composition of this invention that maintained protein integrity and aerosol stability after storage at 30°C, 40°C, 50°C, and temperature cycling at 2 to 37°C.

A 20% insulin aerosol formulation was obtained by preparing a solution of human zinc insulin, mannitol, sodium citrate dihydrate, and citric acid monohydrate. Bulk crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN., and U.S.P. grade excipients were used. The solution contained 2.0 mg insulin, 1.82 mg mannitol, 5.91 mg sodium citrate, 0.006 mg citric acid, and 0.26 mg glycine per milliliter of deionized water for a total solids concentration of 10.0 mg/mL at pH 7.3. Dry powders were prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

	Temperature of aqueous solution	2-8°C
	Inlet temperature	128-130°C
	Outlet temperature	85-88°C
	Flow feed rate	5.0 mL/min
5	Jacketed cyclone temperature	30-31°C

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 85°C for 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.

- 10 Larger batches of powder were prepared by spray-drying a solution containing 2.5 mg insulin, 2.28 mg mannitol, 7.39 mg sodium citrate, 0.007 mg citric acid, and 0.32 mg glycine per milliliter of deionized water for a total solids concentration of 12.5 mg/mL at pH 7.3. A Niro Spray Dryer was used to prepare the dry powder using the following conditions:

15

	Temperature of aqueous solution	2-8°C
	Atomizer chilling water return	2-6°C
	Inlet temperature	143-147°C
	Outlet temperature	79-81°C
20	Atomizer air flow	12 scfm at 41-47 psig
	Flow rate	50 mL/min

Both the Buchi and Niro dry powders (I-004) contained the following solids content:

- 25 20.0 % insulin, 2.6 % glycine, 59.1 % sodium citrate, 18.2% mannitol, 0.1 % citric acid

Characterization and Stability:

Insulin powders were stored desiccated at < 10% relative humidity (unless noted) at 30°C, 40°C, 50°C and at temperature cycling conditions of 2 to 37°C every 24 hours. Stability samples were evaluated for moisture content, aerosol performance based on delivered dose of insulin, and glass transition temperature using differential scanning calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) and aerosol delivered dose testing were carried out as described previously. The aerosol particle size distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing.

Stability data are summarized in Table I below for several powders of this composition prepared on both the Buchi and Niro spray dryers. Within the error of the measurements, the aerosol performance remained unchanged upon storage. Figure 2 shows a DSC thermogram of this insulin formulation stored at 40°C at the 3-4 week timepoint and indicating a T_g of 89°C. The small endotherm preceding the glass transition appeared in all thermograms. It may be due to desorption of water or a denaturing of a small amount of insulin not in the glass phase. A plot of moisture content as a function of glass transition temperature is shown in Figure 3. This formulation was remarkable in the fact that the powder could take up > 5% moisture without loss of aerosol performance.

The effect of moisture on T_g is material specific and must be known in order to achieve a good aerosol product. Even for a glassy material with a high T_g , the potential for crystallization and glass relaxation to the rubbery phase increases with increasing moisture content. The compositional phase diagram for this formulation was characterized by analyzing powders prepared by two methods: 1) exposure of powder to

humid storage conditions and 2) preparation of powders at different moisture contents by altering secondary drying conditions. The results of DSC and moisture analysis are shown in the T_g -moisture profile of Figure 3, showing that the T_g should be above 40°C at moisture contents up to about 4.5 to 5%. The effect of moisture on the powder was further tested by moisture sorption analysis over a range of 10 to 90%RH at 25°C (Figure 4). All the water that is adsorbed can also be desorbed indicating that the powder does not undergo amorphous to crystalline phase changes when exposed to high relative humidity. The absence of any remarkable changes at low to moderate humidity levels is further evidence for the stability of this insulin formulation.

Powders remained amorphous by X-ray diffraction analysis (Figure 5) and polarizing light microscopy. Powder surface area, measured by nitrogen adsorption, ranged from 7 to 10 m²/g for these powders. The particles have a convoluted "raisin" structure rather than a smooth spherical surface by scanning electron microscopy (SEM) analysis (Figure 6). (ESCA) surface chemistry analysis indicated that the particles contained a majority of the insulin on the surface of the particles. That is, ESCA analysis indicated that the surface composition was 52% insulin, 11% glycine, 16% mannitol, and 21% citrate while the overall formulation composition was 20% insulin, 2.6% glycine, 18% mannitol, and 59% citrate.

Table I

Lot No. (Niro or Buchi) I-004	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μm)	% particle mass < 5 μm in size	% moisture	T _g (°C)
R95030 (Buchi)	30	Initial 4 wk 12 wk	70 \pm 4 71 \pm 4 73 \pm 5			1.7 2.0 1.9	90
	cycled 2- 37°C	Initial 2 wk	70 \pm 4 74 \pm 4			1.7 2.0	90
	40	Initial 3-4 wk	70 \pm 4 69 \pm 4			1.7 2.0	90 89
96311 (Niro)	30	Initial	73 \pm 2	2.9	77	2.3	70
		3 wk	75 \pm 7	2.5	85	2.0	
		6 wk	70 \pm 7	2.1	89	3.1	77
		12 wk	68 \pm 5	2.7	75	2.4	75
	40	Initial	73 \pm 2	2.9	77	2.3	70
		3 wk	75 \pm 5	2.4	85	1.9	
		6 wk	67 \pm 5	2.9	74	2.5	72
		12 wk	71 \pm 3	3.0	77	2.1	74
	40°C, 75% RH	Initial	73 \pm 4	2.8, 3.3	73, 83	2.3	70
		1 wk	73 \pm 3	2.8, 2.8	76, 74	2.0	72
		2 wk	74 \pm 2	3.2, 2.5	71, 82	2.3	71
		3 wk	69 \pm 6	2.1, 2.3	91, 89	2.5	65
		4 wk	74 \pm 2	1.5, 1.9	94, 92	2.9	63
		6 wk	72 \pm 3	2.1, 2.6	87, 89	3.4	62
		12 wk	68 \pm 2			5.4	53
		26 wk	52 \pm 4	1.0	95, 96	7.2	34
95318 (Niro)	30	Initial	82 \pm 9	3.4	71	1.9	84
		3 wk	79 \pm 6			2.2	82
		6 wk	89 \pm 6			1.6	84
		12 wk	85 \pm 6	3.3	69	2.0	84
		25 wk	78 \pm 8	3.0	74	1.9	85
	40	Initial	82 \pm 9	3.4	71	1.9	84
		3 wk	77 \pm 5			2.2	84
		12 wk	86 \pm 4			2.0	83

Lot No. (Niro or Buchi) I-004	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μm)	% particle mass < 5 μm in size	% moisture	T _g (°C)
	cycled 2- 37°C	Initial	82 \pm 9	3.4	71	1.9	84
		12 wk	91 \pm 5			1.9	82
	50	Initial	82 \pm 9	3.4	71	1.9	84
		12 wk	81 \pm 8			1.8	84
		25 wk	81 \pm 8	2.7	78		88
95310 (Buchi)	30	Initial	86 \pm 4	2.9	76	1.7	88
		3 wk	81 \pm 7	4.0	62	2.1	88
		6 wk	75 \pm 4	3.9	62	1.8	88
		12 wk	77 \pm 9	3.3	71	1.4	87
		20 wk	80 \pm 6	2.8	74	1.4	89
		12 month	77 \pm 5	3.9	62	1.4	88
	40	Initial	86 \pm 4	2.9	76	1.7	88
		3 wk	83 \pm 3	4.0	68	1.7	89
		6 wk	78 \pm 4	3.5	68	1.6	90
		12 wk	78 \pm 8	3.0	73	1.6	91

Example 3

- 5 This example sets forth a 60% Insulin composition that maintained protein integrity and aerosol stability after storage at 30°C, 40°C, 50°C, and temperature cycling at 2 to 37°C.

A 60% insulin aerosol formulation was obtained by preparing a solution of human zinc insulin, mannitol, sodium citrate dihydrate, and citric acid monohydrate. Bulk
10 crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN., and U.S.P. grade excipients were used. The solution contained 7.50 mg insulin, 1.27 mg mannitol, 3.38 mg sodium citrate, 0.026 mg sodium hydroxide, and 0.32 mg glycine per milliliter of deionized water for a total solids concentration of 12.5 mg/mL at pH 7.3.

A Niro Spray Dryer was used to prepare the dry powder using the following
15 conditions:

	Temperature of aqueous solution	2-8°C
	Atomizer chilling water return	2-6°C
	Inlet temperature	143-147°C
	Outlet temperature	79-81°C
5	Atomizer air flow	12 scfm at 41-47 psig
	Flow rate	50 mL/min

The dry powder (I-016) contained the following solids content: 60.0 % insulin, 2.6% glycine, 27.1 % sodium citrate, 10.1% mannitol, 0.2% sodium ion from sodium
10 hydroxide

Characterization and Stability:

Insulin powders were stored desiccated at < 10% relative humidity (unless noted) at 30°C, 40°C, 50°C and at temperature cycling conditions of 2 to 37°C every 24 hours.
15 Stability samples were evaluated for moisture content, aerosol performance based on delivered dose of insulin, and glass transition temperature using differential scanning calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) and aerosol delivered dose testing were carried out as described previously. The aerosol particle size
20 distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing.

Stability data are summarized below in Table II for several powders of this composition. Within the error of the measurements, the aerosol performance remained unchanged upon storage at dry conditions. This formulation was remarkable in the fact
25 that the powder could take up to 4.6% moisture without a loss of aerosol performance.

The effect of moisture on T_g is presented in Figure 7 showing that the T_g is $> 40^\circ\text{C}$ up to about 5% moisture.

Powders were amorphous by X-ray diffraction analysis. Powder surface area, measured by nitrogen adsorption, ranged from 7 to 10 m^2/g for these powders. The
5 particles have a convoluted "raisin" structure (SEM analysis) rather than a smooth spherical surface.

Table II

	Lot No. (I-016)	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μm)	% particle mass < 5 μm in size	% moisture	T _g (°C)
5	95322	30	Initial	95 \pm 8	2.4	81	2.1	89
			12 wk	92 \pm 7	2.3	81		90
			25 wk	94 \pm 6	3.2	72		89
10		40	Initial	95 \pm 8	2.4	81	2.1	89
			12 wk	93 \pm 6	2.2	81	1.0	not done
			25 wk	93 \pm 5	2.6	76		88
		50	Initial	95 \pm 8	2.4	81	2.1	89
			12 wk	94 \pm 7	2.2	85		84
			25 wk	87 \pm 6	2.8	74		87
15	95322 after vacuum drying	30	Initial	93 \pm 8	2.7	76	1.4	95
			12 wk	96 \pm 6	2.3	83	1.6	94
			25 wk	94 \pm 6	2.8	73	1.6	82
20		40	Initial	93 \pm 8	2.7	76	1.4	95
			12 wk	93 \pm 6			1.4	91
		50	Initial	93 \pm 8	2.7	76	1.4	95
			12 wk	94 \pm 6				85
			25 wk	93 \pm 6	3.2	72		88
25	96317	30	Initial	87 \pm 4	2.9, 3.1	77, 78	1.9	65
			3 wk	78 \pm 4	2.7, 3.4	80, 72	2.0	
			6 wk	83 \pm 3			2.2	64
		40°C, 75 % RH	Initial	87 \pm 4	2.9, 3.1	77, 78	1.9	65
			1 wk	81 \pm 3	2.3, 2.8	95, 80	2.1	59
			2 wk	84 \pm 3	2.9, 2.8	73, 76	1.8	58
			3 wk	82 \pm 3	2.9, 3.4	78, 74	2.4	63
			4 wk	81 \pm 5	3.2, 3.2	74, 76	2.4	63
			6 wk	79 \pm 4	2.8, 3.0	85, 79	3.0	57
			12 wk	79 \pm 5			4.6	47
			26 wk	74 \pm 2	2.8, 3.4	77, 71	5.9	31

Example 4

This example sets forth a 60% insulin composition that maintained protein integrity and aerosol stability after storage at 30°C, 40°C, 50°C, and temperature cycling at 2 to 37°C.

- 5 A 60% insulin aerosol formulation was obtained by preparing a solution of human zinc insulin, mannitol, sodium citrate dihydrate, and citric acid monohydrate. Bulk crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN., and U.S.P. grade excipients were used. The solution contained 7.50 mg insulin, 2.28 mg mannitol, 2.37 mg sodium citrate, 0.023 mg sodium hydroxide, and 0.32 mg glycine per
- 10 milliliter of deionized water for a total solids concentration of 12.5 mg/mL at pH 7.3.
- Dry powders were prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

	Temperature of aqueous solution	2-8°C
15	Inlet temperature	128-130°C
	Outlet temperature	85-88°C
	Feed rate	5.0 mL/min
	Jacketed cyclone temperature	30-31°C

- 20 After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 85°C for 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.

A Niro Spray Dryer was also used to prepare dry powder using the following conditions:

25

	Temperature of aqueous solution	2-8°C
	Atomizer chilling water return	2-6°C
	Inlet temperature	143-147°C
	Outlet temperature	79-81°C
5	Atomizer air flow	12 scfm at 41-47 psig
	Flow rate	50 mL/min

The dry powder (I-005) contained the following solids content:

60.0 % insulin, 2.6% glycine, 19.0 % sodium citrate, 18.3% mannitol, 0.2% sodium ion
10 from sodium hydroxide.

Characterization and Stability:

Insulin powders were stored desiccated at < 10% relative humidity (unless noted)
at 30°C, 40°C, 50°C and at temperature cycling conditions of 2 to 37°C every 24 hours.
15 Stability samples were evaluated for moisture content, aerosol performance based on
delivered dose of insulin, and glass transition temperature using differential scanning
calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) and aerosol
delivered dose testing were carried out as described previously. The aerosol particle size
20 distribution was measured using a cascade impactor (California Measurements IMPAQ-6)
connected to the device described for delivered dose testing.

Stability data are summarized below for several powders of this composition.
Within the error of the measurements, the aerosol performance remained unchanged upon
storage.

Powders were amorphous by X-ray diffraction analysis. Powder surface area, measured by nitrogen adsorption, ranged from 7 to 10 m²/g for these powders. The particles have a convoluted "raisin" structure (SEM analysis) rather than a smooth spherical surface.

5

10

15

20

25

Lot No. (I-005)	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μm)	% particle mass < 5 μm in size	% moisture	T _g (°C)	
95317 (Buchi)	30	Initial	86 ± 5	3.0	74	1.0	54	
		3 wk	87 ± 6	2.7	75	1.4	50	
		6 wk	89 ± 3	2.8	73	1.1	56	
		12 wk	85 ± 7	3.1	72	0.5	51	
		20 wk	92 ± 4	2.3	85	0.9	59	
		12 month	87 ± 5	2.9	76	0.7	62	
	40	Initial	86 ± 5	3.0	74	1.0	54	
		3 wk	86 ± 8	3.0	72	0.8	58	
		6 wk	89 ± 3	2.9	75	1.1	54	
		12 wk	87 ± 7	2.2	83	0.5	48	
	95321 (Niro)	30	Initial	95 ± 4	2.8	78	1.2	58
			3 wk	88 ± 3			1.7	43
6 wk			96 ± 5			0.9	49	
12 wk			92 ± 5	2.4	82	1.2	54	
25 wk			91 ± 4	3.0	74	1.0	55	
40		Initial	95 ± 4	2.8	78	1.2	58	
		3 wk	90 ± 6			1.1	55	
		6 wk	94 ± 5			0.9	64	
		12 wk	91 ± 6			1.1	66	
2- 37 cycled		Initial	95 ± 4	2.8	78	1.2	58	
		12 wk	93 ± 5			1.1	52	

Example 5

30

This example sets forth a 20% insulin composition that maintained protein integrity and aerosol stability after storage at 30°C, 40°C, and temperature cycled from 2 to 37°C.

A 20% insulin aerosol formulation was obtained by preparing a solution of human zinc insulin, glycine, sodium citrate dihydrate, and citric acid monohydrate. Bulk crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN., and U.S.P. grade excipients were used. The solution contained 2.0 mg insulin, 7.73 mg sodium citrate, 0.01 mg citric acid, and 0.26 mg glycine per milliliter of deionized water for a total solids concentration of 10.0 mg/mL at pH 7.3. Dry powders were prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

10	Temperature of aqueous solution	2-8°C
	Inlet temperature	130°C
	Outlet temperature	77°C
	Flow rate	5.2 mL/min
	Jacketed cyclone temperature	30-31°C

15

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 80°C for 1 minute by slowly decreasing the inlet temperature to provide a secondary drying.

Larger batches of powder were prepared by spray-drying a solution containing 2.5 mg insulin, 9.663 mg sodium citrate, 0.012 mg citric acid, and 0.325 mg glycine per milliliter of deionized water for a total solids concentration of 12.5 mg/mL at pH 7.3. A Niro Spray Dryer was used to prepare the dry powder using the following conditions:

	Temperature of aqueous solution	2-8°C
25	Atomizer chilling water return	2-6°C

Inlet temperature	130°C
Outlet temperature	70°C
Atomizer air flow	12 scfm at 41-47 psig
Feed rate	50 mL/min

5

Both the Buchi and Niro dry powders (I-006) contained the following solids content:

20.0 % insulin, 2.6% glycine, 77.3 % sodium citrate, 0.1% citric acid

10 Characterization and Stability:

Insulin powders were stored desiccated at < 10% relative humidity at 30°C, 40°C, and at temperature cycling conditions of 2 to 37°C every 24 hours. Stability samples were evaluated for moisture content, aerosol performance based on delivered dose of insulin, and glass transition temperature using differential scanning calorimetry.

15 Thermal analysis using differential scanning calorimetry (DSC) and aerosol delivered dose testing were carried out as described previously. The aerosol particle size distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing.

Stability data are summarized below for a powder of this composition prepared on both the Buchi and Niro spray dryers. Within the error of the measurements, the aerosol performance remained unchanged upon storage. Powders were amorphous by X-ray diffraction analysis and polarizing light microscopy. Powders exhibit very high T_g (>100°C) even at moisture contents ranging from 3 to 5%.

25

	Lot No. (Niro or Buchi) I-006	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
5	R95032 (Buchi)	30	Initial	70 \pm 3	—	—	3.2	107
			4 wk	70 \pm 4			3.4	
			12 wk	76 \pm 4			2.9	
10		cycled 2- 37°C	Initial	70 \pm 3	—	—	3.2	107
			2 wk	75 \pm 4			3.9	
		40	Initial	70 \pm 3	—	—	3.2	107
			3-4 wk	71 \pm 5			4.6	106

Example 6

This example sets forth a 60% insulin composition that maintained protein integrity and aerosol stability after storage at 30°C, 40°C, and temperature cycling at 2 to 37°C.

A 60% insulin aerosol formulation was obtained by preparing a solution of human zinc insulin, glycine, sodium citrate dihydrate, and sodium hydroxide Bulk crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN., and U.S.P. grade excipients were used. The solution contained 6.0 mg insulin, 3.71 mg sodium citrate, 0.026 mg sodium hydroxide, and 0.26 mg glycine per milliliter of deionized water for a total solids concentration of 10.0 mg/mL at pH 7.3. Dry powders were prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

25	Temperature of aqueous solution	2-8°C
	Inlet temperature	128-130°C
	Outlet temperature	78°C
	Feed rate	5.2 mL/min
	Jacketed cyclone temperature	30-31°C

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 78°C for 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.

Dry powders (I-007) contained the following solids content:

- 5 60.0 % insulin, 2.6% glycine, 37.1 % sodium citrate, 0.3% sodium ion from sodium hydroxide

Characterization and Stability:

- Insulin powders were stored desiccated at < 10% relative humidity at 30°C, 10 40°C, and at temperature cycling conditions of 2 to 37°C every 24 hours. Stability samples were evaluated for moisture content, aerosol performance based on delivered dose of insulin, and glass transition temperature using differential scanning calorimetry.

- Thermal analysis using differential scanning calorimetry (DSC) and aerosol delivered dose testing were carried out as described previously. The aerosol particle size 15 distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing.

- Stability data are summarized below for a powder of this composition prepared on both the Buchi and Niro spray dryers. Within the error of the measurements, the aerosol performance remained unchanged upon storage. Powders were amorphous by X-ray 20 diffraction analysis and polarizing light microscopy. Powders exhibit very high T_g (>100°C). Citrate is an excellent glass former.

Lot No. (Niro or Buchi) I-007	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μm)	% particle mass < 5 μm in size	% moisture	T _g (°C)
R95033 (Buchi)	30	Initial	82 \pm 3			2.1	115
		4 wk	80 \pm 4			2.2	
		12 wk	81 \pm 6			1.6	
	cycled 2- 37°C	Initial	82 \pm 3			2.1	115
		2 wk	87 \pm 3			1.8	
	40	Initial	82 \pm 3			2.1	115
		3-4 wk	83 \pm 5			1.8	

Example 7

This example sets forth a 20% insulin composition of this invention (a partially glassy, partially crystalline powder), which showed good aerosol stability at 30°C, 40°C, and 50°C.

A 20% insulin aerosol formulation was obtained by preparing a solution of human zinc insulin, sucrose, sodium citrate dihydrate, glycine, and sodium hydroxide. Bulk crystalline human zinc insulin, obtained from Eli Lilly and Company, Indianapolis, IN., and U.S.P. grade excipients were used. The solution contained 2.0 mg insulin, 4.74 mg sucrose, 3.00 mg sodium citrate, and 0.26 mg glycine per milliliter of deionized water for a total solids concentration of 10.0 mg/mL at pH 7.3. Dry powders were prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

Temperature of aqueous solution 2-8°C

Inlet temperature 125°C

Outlet temperature 75°C

Feed rate	5.2 mL/min
Jacketed cyclone temperature	30-31°C

After all the aqueous solution was pumped into the spray dryer, the outlet
5 temperature was maintained at 78°C for 5 minutes by slowly decreasing the inlet
temperature to provide a secondary drying.

The dry powder (I-029) contained the following solids content:
20.0 % insulin, 2.6% glycine, 30.0 % sodium citrate, 47.2 sucrose, 0.2% sodium ion
from sodium hydroxide.

10

Characterization and Stability:

Insulin powders were stored desiccated at < 10% relative humidity (unless noted)
at 30°C, 40°C, 50°C and at temperature cycling conditions of 2 to 37°C every 24 hours.
Stability samples were evaluated for moisture content, aerosol performance based on
15 delivered dose of insulin, and glass transition temperature using differential scanning
calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) and aerosol
delivered dose testing were carried out as described previously. The aerosol particle size
distribution was measured using a cascade impactor (California Measurements IMPAQ-6)
20 connected to the device described for delivered dose testing.

Stability data are summarized below for several powders of this composition.
Within the error of the measurements, the aerosol performance remained unchanged upon
storage. Powders were predominantly glassy (T_g of 98°C) with some crystallinity
observed by polarizing light microscopy.

25

5

Lot No. (I-029)	Storage Temp (°C)	Storage Time	% Del. Dose	MMAD (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
R95084 (Buchi)	30	Initial	78 \pm 6	2.9	74	1.2	98
		6 wk	76 \pm 1				
		12 wk	72 \pm 4	2.6	80		
	40	Initial	78 \pm 6	2.9	74	1.2	98
		12 wk	74 \pm 4				

Example 8

10 This example sets forth a 0.7% Interleukin-1 Receptor composition that maintained aerosol stability after storage at room temperature for 13 months.

Interleukin-1-receptor aerosol formulations were obtained by preparing solutions of human recombinant Interleukin-1 receptor (rhu IL-1R), tromethaminehydrochloride (TRIS HCl), tromethamine (TRIS), and raffinose pentahydrate. Human recombinant IL-1R,
 15 obtained from Immunex Corporation, Seattle, WA, U.S.P. grade tromethamine, A.C.S. grade tromethamine hydrochloride, and GMP-qualified raffinose pentahydrate (Pfanstiehl, Waukegan, IL) were used. The 0.7% rhu IL-1 R formulation was achieved by combining 0.053 mg rhu IL-1R per 1.0 mL deionized water with 7.07 mg/mL raffinose and 0.373 mg/mL Tris buffer at pH 7.18.

20 A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

Temperature of aqueous solution	2-8°C
Inlet temperature	135-137°C
25 Outlet temperature	92-93°C
Feed rate	4.9 mL/min

Jacketed cyclone temp

30°C

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 90°C for 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying. The dry powder contained the following solids content: 0.7 % rhu IL-1R, 94.3% raffinose, and 5.0% Tris buffer.

Characterization and Stability:

RHu IL-1R powders were stored desiccated at < 10% relative humidity at 30°C.

Stability samples were evaluated for moisture content, aerosol performance based on delivered dose and cascade impaction particle size distribution, and glass transition temperature using differential scanning calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) and aerosol delivered dose testing were carried out as described previously. The aerosol particle size distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing and showed a stable aerosol performance.

Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMAD (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
30	Initial	53 \pm 5	3.2	77	1.8	71
	3 mo	60 \pm 15	3.0	76	1.6	
	6 mo	61 \pm 5	3.2	81	1.5	
	13 mo	51 \pm 7	2.7	86	0.9	

Example 9

This example sets forth a 5.0% Interleukin-1 Receptor composition that maintained aerosol stability after storage at room temperature for 3 months.

Interleukin-1-receptor aerosol formulations were obtained by preparing solutions of human recombinant Interleukin-1 receptor (rhu IL-1R), tromethaminehydrochloride (TRIS HCl), tromethamine (TRIS), and raffinose pentahydrate. Human recombinant IL-1R, obtained from Immunex Corporation, Seattle, WA, U.S.P. grade tromethamine, A.C.S. grade tromethamine hydrochloride, and GMP-qualified raffinose pentahydrate (Pfanstiehl, Waukegan, IL) were used. The 5.0% rhu IL-1 R formulation was achieved by combining 0.375 mg rhu IL-1R per 1.0 mL deionized water with 6.77 mg/mL raffinose and 0.351 mg/mL Tris buffer at pH 7.35.

A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

15	Temperature of aqueous solution	2-8°C
	Inlet temperature	138°C
	Outlet temperature	91°C
	Feed rate	4.9 mL/min
	Jacketed cyclone temp	30°C

20

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 90°C for 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying. The dry powder contained the following solids content: 5.0 % rhu IL-1R, 90.3 % raffinose, and 4.7% Tris buffer.

25

Characterization and Stability:

Rhu IL-1R powders were stored desiccated at < 10% relative humidity at 30°C. Stability samples were evaluated for moisture content, aerosol performance based on delivered dose and cascade impaction particle size distribution, and glass transition temperature using differential scanning calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) and aerosol delivered dose testing were carried out as described previously. The aerosol particle size distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing.

Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMAD (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
30	Initial	49 \pm 10	4.1	64	1.8	71
	3 mo	56 \pm 7	3.5	77	2.1	

Example 10

This example sets forth a 1.0% Interleukin-1 Receptor composition that maintained aerosol stability after storage at room temperature for 2.5 years at 30°C and 47% RH.

Interleukin-1-receptor aerosol formulations were obtained by preparing solutions of human recombinant Interleukin-1 receptor (rhu IL-1R), tromethaminehydrochloride (TRIS HCl), tromethamine (TRIS), and raffinose pentahydrate. Human recombinant IL-1R, obtained from Immunex Corporation, Seattle, WA, U.S.P. grade tromethamine, A.C.S. grade tromethamine hydrochloride, and GMP-qualified raffinose pentahydrate (Pfanstiehl, Waukegan, IL) were used. The 1.0% rhu IL-1 R formulation was achieved by combining 0.375 mg rhu IL-1R per 1.0 mL deionized water with 6.77 mg/mL raffinose and 0.351 mg/mL Tris buffer at pH 7.1.

A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

	Temperature of aqueous solution	2-8°C
5	Inlet temperature	140°C
	Outlet temperature	90-92°C
	Feed rate	5.3 mL/min
	Jacketed cyclone temp	30°C

10 After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 90°C for 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying. The dry powder contained the following solids content: 1.0 % rhu IL-1R, 94.3% raffinose, and 4.7% Tris buffer.

15 Characterization and Stability:

Rhu IL-1R powders were stored desiccated at approximately 47% relative humidity (using a chamber containing a saturated solution of potassium thiocyanate) at 30°C. Stability samples were evaluated for moisture content, aerosol performance based on delivered dose and cascade impaction particle size distribution, and glass transition
20 temperature using differential scanning calorimetry.

Thermal analysis and aerosol delivered dose testing were carried out as described previously. A DSC scan showed a T_g of 71°C for the initial measurement (see Figure 14). The aerosol particle size distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose
25 testing. The aerosol data was collected using an early version of the device. The

variability in the particle size data is probably not due to stability differences but rather variable performance of this powder in the early version of this device. The similarity in the data at 2 weeks and 2.5 years storage supports this conclusion, as well as the stability data presented in Example 8 for a similar powder.

5

Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMAD (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
30°, 47% RH	Initial	42 \pm 5	3.0	83	1.6	71
	2 wk	54 \pm 12	3.9	66	1.7	
	6 wk	54 \pm 5	2.8	82	2.4	
	2.5 years	52 \pm 12	3.5	61	4.5	

10

Example 11

This example sets forth a 8.0% Interleukin-1 Receptor composition that maintained aerosol stability after storage at room temperature for 2.5 years at 30°C and 47% RH.

Interleukin-1-receptor aerosol formulations were obtained by preparing solutions of human recombinant Interleukin-1 receptor (rhu IL-1R), tromethaminehydrochloride (TRIS HCl), tromethamine (TRIS), and raffinose pentahydrate. Human recombinant IL-1R, obtained from Immunex Corporation, Seattle, WA, U.S.P. grade tromethamine, A.C.S. grade tromethamine hydrochloride, and GMP-qualified raffinose pentahydrate (Pfanstiehl, Waukegan, IL) were used. The 8.0% rhu IL-1 R formulation was achieved by combining 0.600 mg rhu IL-1R per 1.0 mL deionized water with 6.55 mg/mL raffinose and 0.351 mg/mL Tris buffer at pH 7.30.

20

A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

25

Temperature of aqueous solution

2-8°C

Inlet temperature	142°C
Outlet temperature	91-92°C
Feed rate	5.3 mL/min
Jacketed cyclone temp	30°C

5

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 90-92°C for 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying. The dry powder contained the following solids content: 8.0 % rhu IL-1R, 87.3% raffinose, and 4.7% Tris buffer.

10

Characterization and Stability:

Rhu IL-1R powders were stored desiccated at approximately 47% relative humidity (using a chamber containing a saturated solution of potassium thiocyanate at 30°C).

Stability samples were evaluated for moisture content, aerosol performance based on delivered dose and cascade impaction particle size distribution, and glass transition temperature using differential scanning calorimetry or dielectric relaxation thermal analysis (DER).

Thermal analysis using DER was accomplished using a dielectric thermal analyzer (Thermal Analysis Instruments) set up in a dry box at < 5% relative humidity. Figure 8 sets forth a DER scan from 0°C to about 100°C at 1°C/min. that was run on the formulation after 2.5 years. Here, as with the other DER analyses, the onset is used. The sample was supercooled to -70°C and then scanned and data collected as the sample was warmed. Aerosol delivered dose testing was carried out as described previously. The aerosol particle size distribution was measured using a cascade impactor (California Measurements IMPAQ-6) connected to the device described for delivered dose testing.

25

The 2.5 year storage results for delivered dose were remarkable because the powder had gained 3.3% moisture. The percent of the particle mass < 5 μm may have decreased slightly or more likely was a result of the variability of this powder's performance in the early version of the device used for testing. The particle size distribution is shown in Figure 9A, the initial timepoint, and Figure 9B, after 2 weeks at 30°C and 47% RH, and shows stable dispersibility over time.

10

Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMAD (μm)	% particle mass < 5 μm in size	% moisture	T _g (°C)
30°, 47% RH	Initial	47 \pm 13	3.4	74	1.2	71 (DSC)
	2 wk	55 \pm 11	3.3	72	1.2	
	6 wk	43 \pm 10	2.9	80	1.6	
	2.5 years	49 \pm 9	3.7	63	4.5	59 (DER)

Example 12

15

This example sets forth a composition that maintained aerosol stability after storage for 11 months at 30°C.

The formulation was obtained by preparing solutions of tromethaminehydrochloride (TRIS HCl), tromethamine (TRIS), and raffinose pentahydrate (Pfanstiehl, Waukegan, IL). The raffinose/Tris formulation was achieved by combining 7.15 mg/mL raffinose and 0.351 mg/mL Tris buffer at pH 7.1.

20

A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

Temperature of aqueous solution 2-8°C

Inlet temperature 118-120°C

Outlet temperature

81°C

Feed rate

5.8 mL/min

The dry powder contained the following solids content: 95.3% raffinose, and
 5 4.7% Tris buffer.

Characterization and Stability:

The raffinose/Tris powder was stored desiccated at 30°C. Stability samples were
 evaluated for moisture content, aerosol performance based on delivered dose and cascade
 10 impaction particle size distribution, and glass transition temperature using differential
 scanning calorimetry. Thermal analysis and aerosol delivered dose testing were carried
 out as described previously. The aerosol particle size distribution was measured using a
 cascade impactor (California Measurements IMPAQ-6) connected to the device described
 for delivered dose testing. Although the powder was a poor aerosol powder with only
 15 26% delivered dose and a high relative standard deviation initially, the powder was stable
 for 11 months.

Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMAD (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
20 30°	Initial	26 \pm 39	3.9	74	1.1	60
	3 month	23 \pm 7	2.8	72	0.7	
	6 month	18 \pm 9	2.6	79	0.7	
	11 month	22 \pm 14	3.5	53	0.5	

Example 13

This example sets forth 90% alpha-1 Antitrypsin composition showing stability for 13 months at ambient room temperature.

A 90% Alpha-1 Antitrypsin aerosol formulation was obtained by preparing a solution of purified human Alpha-1 Antitrypsin, sodium citrate dihydrate, and citric acid monohydrate. Bulk purified human Alpha-1 Antitrypsin solution in pH 6.0 sodium citrate buffer was obtained from Armour Pharmaceutical, Kankakee, IL.. A.C.S./U.S.P. grade excipients were used. The solution contained 4.99 mg human Alpha-1 Antitrypsin, 0.455 mg sodium citrate, 0.0082 mg citric acid per milliliter of deionized water for a total solids concentration of 5.5 mg/mL at pH 6.0.

A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

Temperature of aqueous solution	2-8°C
Inlet temperature	98-100°C
Outlet temperature	63-66°C
Feed rate	5.3 mL/min
Jacketed cyclone temp	30°C

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 71-73°C for 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying. The dry powder was prepared to contain the following solids content: 90.3 % rhu Human Alpha-1 Antitrypsin and 9.7% citrate buffer.

Characterization and Stability:

Human Alpha-1 Antitrypsin powder was stored desiccated at < 10% relative humidity (unless noted) at ambient room temperature. The initial UV spectrophotometric assay of the powder showed that the powder contained 82% alpha-1 antitrypsin in the solid, rather than the expected 90% concentration based on the bulk protein concentration. The human alpha-1 antitrypsin powder was reconstituted in water and analyzed for protein integrity by size exclusion and reversed phase chromatography, SDS-PAGE electrophoresis, and trypsin chromogenic bioassay. No protein degradation was detected by any method. Powder stability samples were evaluated for moisture content, aerosol performance based on delivered dose of insulin, and glass transition temperature using dielectric thermal analysis.

Thermal analysis and aerosol delivered dose testing were carried out as described previously. A single T_g at 40°C followed by a softening or denaturation endotherm at about 160°C was observed initially for this formulation by DSC analysis. At the end of study, thermal analysis was carried out by DER. DER showed a small change in dielectric constant at 39°C and another T_g with pronounced change in dielectric mobility at 93°C. The delivered dose was unchanged after 13 months storage.

Stability data are summarized below for several powders of this composition.

Lot No.	Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMA D (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
95011	Ambient	Initial	58 \pm 4 64 \pm 3	1.3	90	3.9	40
		3 month	67 \pm 8				
		4 month	72 \pm 3	1.7, 1.3	86, 90	2.8	
		6 month	73 \pm 8				
		13 month	62 \pm 13			2.8, 2.3, 2.6	39, 93 (DER)

5

Example 14

This example sets forth a 5% Human Serum Albumin composition showing aerosol stability for 6 months at 30°C, 40°C, and temperature cycled from 2 to 37°C.

A 5% human serum albumin aerosol formulation was obtained by preparing a solution of recombinant human serum albumin, mannitol, sodium citrate dihydrate, and citric acid monohydrate. Bulk human serum albumin solution was obtained from Miles Inc., Kankakee, IL (Pentex Fr V, Low Endotoxin, Fatty Acid Free). A.C.S./U.S.P. grade excipients were used. The solution contained 1.25 mg human serum albumin, 20.30 mg mannitol, 3.28 mg sodium citrate, 0.17 mg citric acid per milliliter of deionized water for a total solids concentration of 25.0 mg/mL at pH 6.6.

15

A Niro Spray Dryer was used to prepare the dry powder using the following conditions:

Temperature of aqueous solution	2-8°C
Atomizer chilling water return	2-6°C
Inlet temperature	120°C

20

Outlet temperature	60.5-62.8°C
Atomizer air flow	11-12 scfm at 43 psig
Solution feed rate	50 mL/min

- 5 The dry powder was prepared to contain the following solids content: 5.0 %
human serum albumin, 81.1 % mannitol, and 13.8% citrate buffer.

Characterization and Stability:

- Human serum albumin powder was stored desiccated at < 10% relative humidity
10 at 30°C and 40°C. Powder stability samples were evaluated for moisture content, aerosol
performance based on delivered dose, polarizing light microscopy, and glass transition
temperature using DER.

- Thermal analysis and aerosol delivered dose testing were carried out as described
previously. The aerosol particle size distribution was measured using a cascade impactor
15 (Andersen model) connected to the device described for delivered dose testing. The
powder contained a significant amount of crystallinity by polarizing light microscopy
(estimated to be at least half of the particle mass). Thermal analysis showed that the
amorphous phase had a glass transition temperature of 73°C (see Figure 10). Aerosol
performance was consistent over the 6 months storage.

- 20 Stability data are summarized below for a powder of this composition.

Lot No.	Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMAD (μ m)	% particle mass $< 5\mu$ m in size	% moisture	T _g (°C)
NR9508	30	Initial	53 \pm 4			1.2	
		3 month	59 \pm 5				
		6 month	51 \pm 6				
	cycled 2-37°C	Initial	53 \pm 4			1.2	
		3 month	57 \pm 5				
		6 month	51 \pm 6				
	40	Initial	53 \pm 4			1.2	
		3 month	60 \pm 4				
		6 month	50 \pm 8				73 (DER)

Example 15

5 This example sets forth a 2% albuterol composition (lot AS024) showing aerosol stability for 6 weeks at 30°C, 40°C, and temperature cycled from 2 to 40°C.

A 2.3 % Albuterol sulfate (ie, 2% albuterol) formulation was obtained by preparing a solution of albuterol sulfate and lactose. Bulk albuterol sulfate was obtained from Profarmaco (Milano, Italy). U.S.P. grade lactose was used. The solution contained

10 0.60 mg albuterol sulfate and 25.68 mg lactose per milliliter of deionized water for a total solids concentration of 26.28 mg/mL at a pH of 4.6.

A Niro Spray Dryer was used to prepare the dry powder using the following conditions:

15	Temperature of aqueous solution	2-8°C
	Atomizer chilling water return	2-6°C
	Inlet temperature	120°C
	Outlet temperature	64.7-67.2°C
	Atomizer air flow	12 scfm at 43 psig

Solution feed rate

50 mL/min

The dry powder was prepared to contain the following solids content: 2.3 %
albuterol sulfate and 97.7% lactose. The powder was sifted through a 35 mesh sieve after
5 spray drying and before filling into blister packs at 5 mg per pack.

Characterization and Stability:

Albuterol powder was stored desiccated at < 10% relative humidity at 30°C,
40°C, and temperature cycling from 2 to 40°C at 12 hour cycle intervals. Powder
10 stability samples were evaluated for moisture content, aerosol performance based on
delivered dose, polarizing light microscopy, moisture isotherm analysis and glass
transition temperature using DSC.

Thermal analysis and aerosol delivered dose testing were carried out as described
previously, with a DSC scan rate of 2.5°C/minute instead of 1°C/minute. The aerosol
15 particle size distribution was measured using a cascade impactor (California
Measurements) connected to the device described for delivered dose testing. The powder
was amorphous by polarizing light microscopy. Thermal analysis showed a T_g of 83°C.
Aerosol performance was consistent over 6 weeks storage.

The 2% albuterol lactose powder was amorphous by polarizing light microscopy,
20 DSC, and X-ray diffraction analysis. A DSC plot is given in Figure 11 showing the
glass transition temperature of 83°C. The X-ray diffraction pattern, shown in Figure 12,
has a broad halo pattern which corresponds to low angle order in the material and is
characteristic of a glassy amorphous material.

As a material is plasticized by increasing moisture content, the T_g decreases (as
25 well as T_g-T_c) and the potential for crystallization increases. This is demonstrated by the

moisture sorption isotherm at 25°C shown in Figure 13. For the 2% albuterol/lactose formulation, the moisture uptake increases with humidity until 60% relative humidity is reached, where there is a sharp decrease in weight gain as the lactose monohydrate crystal is formed. At this point, the powder converted from amorphous to crystalline, which was confirmed by polarizing light microscopy before and after the moisture sorption experiment. The changes in solid state for this powder occurred at relative humidities that are significantly higher than the desiccated storage condition for the powder.

Stability data are summarized below for a powder of this composition.

Lot No.	Storage Temp (°C)	Storage Time	% Del. Dose ± RSD	MMAD (μm)	% particle mass < 5μm in size	% moisture	T _g (°C)
AS024	30	Initial	55 ± 6	3.6, 3.0	62, 74	2.3	83
		3 wk	51 ± 12	3.5, 3.6	63, 63		
		6 wk	52 ± 12	3.7, 3.0	61, 74		
	cycled 2-40°C	Initial	55 ± 6	3.6, 3.0	62, 74	2.3	
		3 wk	52 ± 7	3.8, 4.4	60, 54		
		6 wk	55 ± 8	3.1, 4.0	71, 60		
	40	Initial	55 ± 6	3.6, 3.0	62, 74	2.3	
		3 wk	52 ± 8	4.6, 3.9	54, 60		
		6 wk	55 ± 10	3.7, 4.2	62, 58		

Example 16

This example sets forth a 5% albuterol composition showing aerosol stability for 6 weeks at 30°C, 40°C, and temperature cycled from 2 to 40°C for 12 hour cycle intervals

A 5.7 % Albuterol sulfate (5% albuterol) formulation was obtained by preparing a solution of albuterol sulfate and lactose. Bulk albuterol sulfate was obtained from Profarmaco (Milano, Italy). U.S.P. grade lactose was used. The solution contained 1.50 mg albuterol sulfate and 24.74 mg lactose per milliliter of deionized water for a total solids concentration of 26.24 mg/mL at a pH of 4.7.

A Niro Spray Dryer was used to prepare the dry powder using the following conditions:

	Temperature of aqueous solution	2-8°C
5	Atomizer chilling water return	2-6°C
	Inlet temperature	115°C
	Outlet temperature	62°C
	Atomizer air flow	12 scfm at 43 psig
	Solution feed rate	55 mL/min

10

The dry powder was prepared to contain the following solids content: 5.7 % albuterol sulfate and 94.3% lactose. The powder was sifted through a 35 mesh sieve after spray drying and before filling into blister packs at 5 mg per pack.

15 Characterization of stability

Albuterol powder was stored desiccated at < 10% relative humidity at 30°C, 40°C, and temperature cycling from 2 to 40°C at 12 hour cycle intervals. Powder stability samples were evaluated for moisture content, aerosol performance based on delivered dose, polarizing light microscopy, moisture isotherm analysis and glass transition temperature using DSC.

20

Thermal analysis and aerosol delivered dose testing were carried out as described previously. The aerosol particle size distribution was measured using a cascade impactor (California Measurements) connected to the device described for delivered dose testing. The powder was amorphous by polarizing light microscopy. Thermal analysis showed a T_g of 95°C. Aerosol performance was consistent over 12 weeks storage.

25

Stability data are summarized below for several powders of this composition.

Lot No.	Storage Temp (°C)	Storage Time	% Del. Dose \pm RSD	MMA D (μ m)	% particle mass < 5 μ m in size	% moisture	T _g (°C)
AS020	30	Initial	50 \pm 13	2.5, 2.2	83, 90	2.6	95
		6 wk	43 \pm 15	3.4, 2.7	71, 80		
		12 wk	43 \pm 9	3.7, 3.0	69, 64		
	40	Initial	50 \pm 13	2.5, 2.2	83, 90	2.6	
		6 wk	50 \pm 8	2.6, 2.8	82, 81		
		12 wk	43 \pm 16	2.9	92, 77		

5

Example 17

This example sets forth a 3.0% salmon calcitonin composition that maintained aerosol stability after storage at room temperature for 8 weeks.

Salmon calcitonin (MW 3431) aerosol formulations was obtained by preparing solutions of salmon calcitonin, mannitol, sodium citrate dihydrate, and citric acid monohydrate. Salmon calcitonin, obtained from Bachem, Torrance, CA, U.S.P. grade excipients were used. The 3.0% salmon calcitonin solution was achieved by combining 0.225 mg salmon calcitonin per 1.0 mL deionized water with 0.75 mg/mL mannitol, 3.88 mg/mL sodium citrate and 2.64 mg/mL citric acid at pH 4.5.

A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

Temperature of aqueous solution 2-8°C

Inlet temperature 130°C

Outlet temperature	76°C
Feed rate	5.0 mL/min
Jacketed cyclone temp	30°C

5 After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 75-77°C for 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying. The dry powder contained the following solids content: 3.0% salmon calcitonin, 10.0 % mannitol, 51.7% sodium citrate, and 35.3% citric acid.

10

Characterization and Stability:

Salmon calcitonin powder was stored desiccated at < 10% relative humidity at ambient room temperature, 30°C, 40°C, and 80°C. Stability samples were evaluated for moisture content, aerosol performance based on delivered dose and cascade impaction
15 particle size distribution, and glass transition temperature using differential scanning calorimetry.

Thermal analysis using differential scanning calorimetry (DSC) was carried out as described previously except that a scan rate of 2.5°C/minute was used. The aerosol particle size distribution was measured using a cascade impactor (California
20 Measurements IMPAQ-6) connected to the device described for delivered dose testing. Aerosol and DSC data are shown below. The glass transition temperature, moisture content, and aerosol results were consistent over the 8 week period at 40°C. The powder showed stable aerosol performance when stored below the T_g and even above the T_g for 4 hours at 80°C. However, after aging the powder for 8 hours at 80°C, the delivered dose
25 efficiency declined, as would be expected for storage 10°C above the glass transition

temperature. The chemical stability of salmon calcitonin in the powder, in contrast, was stable after 8 hours at 80°C. Reverse phase HPLC showed no changes in purity of the drug while physical stability was more sensitive to the difference in storage temperature and T_g .

Storage Temp (°C)	Storage Time	% Del. Dose	% moisture	T_g (°C)
Ambient RT	Initial	63 ± 5	0.9	68
	14 wks	60 ± 5	0.8	71
30	4 wks	59 ± 6	1.2	68
	8 wks	58 ± 6	1.0	
40	4 wks	56 ± 8	1.6	72
	8 wks	57 ± 4	1.0	
80	4 hours	59 ± 5		
	8 hours	28 ± 3		

Example 18

This example sets forth 0.34% elcatonin compositions. Three formulations of elcatonin were prepared by spray drying.

Elcatonin powder formulations were obtained by preparing solutions of elcatonin and glass formers and additives. Elcatonin was obtained from Asahi Chemical Industry Company, Ltd. (Tokyo, Japan). U.S.P. grade povidone (PVP K-15 from ISP Technologies, Wayne, NJ) and sodium citrate were used. Pectin was reagent grade (Sigma).

The 0.34% elcatonin/70% povidone/30% citrate solution was achieved by combining 25.5 μ g elcatonin per 1.0 mL deionized water with 5.25 mg/mL PVP K-15, and 2.25 sodium citrate buffer at pH 5.5. The 0.34% elcatonin/90% povidone/10% citrate solution was achieved by combining 25.5 μ g elcatonin per 1.0 mL deionized water with 6.75 mg/mL PVP K-15, and 0.75 mg/mL sodium citrate buffer at pH 5.5. Dry powders were prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

	Temperature of aqueous solution	2-8°C
	Inlet temperature	140°C
	Outlet temperature	88°C
	Feed rate	5.0 mL/min
5	Jacketed cyclone temp	30°C

After all the aqueous solution was pumped into the spray dryer, the outlet temperature was maintained at 88°C for 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.

10 The 0.34% elcatonin/50% povidone/50% citrate solution was achieved by combining 25.5 µg elcatonin per 1.0 mL deionized water with 3.75 mg/mL pectin, and 3.75 mg/mL sodium citrate buffer at pH 5.5. A dry powder was prepared by spray-drying the aqueous solution using a Buchi Laboratory Spray Dryer under the following conditions:

15

	Temperature of aqueous solution	2-8°C
	Inlet temperature	125°C
	Outlet temperature	76°C
	Feed rate	5.0 mL/min
20	Jacketed cyclone temp	30°C

Characterization

Elcatonin powders were analyzed by aerosol testing, dielectric thermal analysis,
25 and moisture content as described previously. The powders were suspended and

dispersed in a hexane mixture (Sedisperse, Micromeritics) and analyzed for primary particle size distribution by centrifugal sedimentation using an Horiba Particle Size Analyzer.

The powders look promising with suitably high T_g for powder stability and initial aerosol delivered dose greater than 50%. Results are shown in the table.

Formulation	Mass Median Diameter (Horiba)	% < 5 μ M (Horiba)	Del. Dose (%)	Moisture Content (%)	T_g (DER)
0.3% elcatonin/ 70% PVP/30% citrate	1.6	89	53 \pm 16	0.9	48
0.3% elcatonin/ 90% PVP/10% citrate	2.1	100	59 \pm 4	1.1	47
0.3% elcatonin/ 50% pectin/50% citrate	2.1	95	51 \pm 10	2.1	57

Example 19

This example sets forth additional data from a 20% insulin composition identical to that presented in Example 2.

The insulin powder (I-004, lot 96313) was packaged in a foil overwrap with desiccant and stored at 30°C, 50°C, 70°C, and 90°C. The residual moisture content, glass transition temperature and aerosol performance were monitored with the methods described in example 2. The stability results are summarized in the table below. The moisture content remained constant over the period of the study. There was no statistical difference between the initial delivered dose and the delivered dose after six weeks of storage at 30°C, 50°C, and 70°C. After six weeks at 90°C the aerosol performance decreased by approximately 30%. The dispersibility of this composition became unstable

after storage at a temperature of $T_g - T_s < 10^\circ\text{C}$. N/A indicates that the measurement at this point was not made.

5

Lot No. Form. ID	Temp ($^\circ\text{C}$)	Time (weeks)	% Del. Dose (P2.2)	% H ₂ O	T _g ($^\circ\text{C}$)
96313 (I-004) Niro	30	0	76 ± 4	2.0	65
		3	72 ± 4	2.0	68
		6	77 ± 2	2.8	70
		9	N/A	N/A	68
	50	3	74 ± 2	2.0	75
		6	72 ± 3	2.4	72
		9	N/A	N/A	74
	70	3	67 ± 4	2.0	77
		6	72 ± 2	2.0	80
		9	N/A	N/A	81
	90	3	40 ± 5	0.85	89
		6	40 ± 5	1.4	93
		9	N/A	N/A	92

10

Example 20

This example sets forth additional data from a 60% insulin composition identical to that presented in Example 3.

15

The insulin powder (I-016, lot 96317) was packaged in foil overwrap with desiccant and stored at 30°C , 50°C , 70°C , and 90°C . The residual moisture content, glass transition temperature and aerosol performance were monitored with the methods described in example 3. The stability results are summarized in the table below. The moisture content remained constant over the period of the study. There was no statistical difference between the initial delivered dose and the delivered dose after six weeks of storage at 30°C and 50°C . After six weeks at 70°C and 90°C the aerosol performance decreased by approximately 10% and 30%, respectively. The dispersibility of this composition became unstable after storage at a temperature of $T_g - T_s < 10^\circ\text{C}$. N/A indicates that the measurement at this point was not made.

25

5

Lot No. Form. ID	Temp (°C)	Time (weeks)	% Del. Dose (P2.2)	% H ₂ O	T _g (°C)
96317 (I-016) Niro	30	0	84 ± 2	2.4	65
		3	82 ± 4	1.5	70
		6	79 ± 4	2.4	57
		9	N/A	N/A	62
	50	3	79 ± 4	1.6	66
		6	78 ± 4	1.8	59
		9	N/A	N/A	65
	70	3	81 ± 7	1.4	67
		6	72 ± 3	1.8	66
		9	N/A	N/A	72
	90	3	52 ± 3	0.9	69
		6	51 ± 5	2.2	70
		9	N/A	N/A	77

What is claimed is:

1. A powdered, dispersible composition having stable dispersibility over time, a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10°C, which composition comprises a mixture of
 - a pharmaceutically-acceptable glassy matrix and
 - at least one pharmacologically active material within the glassy matrix.
2. A powdered dispersible composition in unit dosage form having stable dispersibility over time and a characteristic glass transition temperature (T_g), in combination with labelling instructions for treating pulmonary or systemic disease in a mammalian subject that include a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10°C, which composition comprises a pharmaceutically acceptable glassy matrix and at least one pharmaceutically active material within the amorphous glassy matrix.
3. The composition of Claim 1 or 2, wherein the difference between T_g and T_s is at least about 20°C.
4. The composition of Claim 1 or 2, wherein the difference between T_g and T_s is at least about 30°C.
5. The composition of Claim 1 or 2, wherein the T_g is about 35°C to about 200°C.

6. The composition of Claim 1 or 2, wherein the T_g is greater than about 45°C.
7. The composition of Claim 1 or 2, wherein the T_g is greater than about 55°C.
- 5 8. The composition of Claim 1 or 2, wherein T_i is about 2°C to about 30°C and T_g is about 22°C to about 200°C.
9. The composition of Claim 1 or 2, wherein the glassy matrix comprises a glass former chosen from the group consisting of carbohydrates, carbohydrate derivatives, carbohydrate polymers, organic carboxylic salts, synthetic organic polymers, proteins, peptides, amino acids and mixtures thereof.
- 10 10. The composition of Claim 1 or 2, wherein the glass former is sodium citrate, raffinose, lactose, trehalose, maltotriose, maltodextrin, maltose, glucopyranosyl-sorbitol, glucopyranosyl-mannitol, polydextrose, sucrose cyclodextrin, casein, HSA, hydroxyethyl starch, stachyose, magnesium gluconate, cellobiose, or a mixture of two or more of the foregoing.
- 15 11. A process for producing a powdered dispersible composition having stable dispersibility over time, a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_i) wherein the difference between T_g and T_i is at least about 10°C, which process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the pharmacologically active material within the matrix.
- 25

12. The process of Claim 11, wherein the solvent is removed by spray drying.
13. The process of Claim 11, wherein the solvent is removed by evaporative drying.
- 5 14. The process of claim 11, wherein the solvent is removed by chemical precipitation.
15. The process of Claim 11, wherein the solvent is water.
- 10 16. The process of Claim 11, wherein the solvent is ethanol.
17. A powdered, dispersible composition having stable dispersibility over time, which composition comprises
- (a) a first, respirable powdered component having a characteristic glass
- 15 transition temperature (T_g) and a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10°C, which composition comprises a mixture of
- a pharmaceutically-acceptable glassy matrix and
- at least one pharmacologically active material within the glassy matrix, and
- 20 (b) a second, nonrespirable powdered component comprising a powdered, pharmaceutically-acceptable carrier.
18. The composition of Claim 17, wherein the largest particle size of the first component is about 10 microns, with the majority of the particles between about 1 micron

to about 5 microns, and the particle size of the second component is between about 15 microns to about 100 microns.

19. The combination of Claim 2, wherein the unit dosage form includes a moisture
5 barrier.

1/10




FIG. 1A




FIG. 1B

2/10




FIG. 2




FIG. 3

3/10





FIG. 4



X-ray diffraction pattern for I-004 formulation. The absence of sharp peaks in this pattern shows that this sample was amorphous.

FIG. 5

4 / 10




FIG.6

5/10




FIG. 7






FIG. 8

6/10

*FIG. 9A**FIG. 9B*

7/10




FIG. 10




FIG. 14

8/10




FIG. 11

9/10




FIG. 12

10/10




FIG. 13



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/14, 9/72	A3	(11) International Publication Number: WO 98/16205 (43) International Publication Date: 23 April 1998 (23.04.98)
<p>(21) International Application Number: PCT/US97/18901</p> <p>(22) International Filing Date: 14 October 1997 (14.10.97)</p> <p>(30) Priority Data: 08/733,225 17 October 1996 (17.10.96) US</p> <p>(71) Applicant (for all designated States except US): INHALE THERAPEUTIC SYSTEMS [US/US]; 1060 East Meadow Circle, Palo Alto, CA 94303 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): FOSTER, Linda, C. [US/US]; Apartment 31, 575 South Rengstorff Avenue, Mountain View, CA 94040 (US). KUO, Mei-chang [US/US]; 1823 Middlefield Road, Palo Alto, CA 949301 (US). BILLINGSLEY, Sheila, R. [US/US]; 665 Kirkland Drive #6, Sunnyvale, CA 94087 (US).</p> <p>(74) Agents: MORAN, Tom, M.; Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306-2155 (US) et al.</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> <p>(88) Date of publication of the international search report: 3 September 1998 (03.09.98)</p>	
<p>(54) Title: STABLE GLASSY STATE POWDER FORMULATIONS</p> <p>(57) Abstract</p> <p>A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10 °C (i.e. $T_g - T_s$ is greater than 10 °C). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions. A process for producing a powdered dispersible composition is also provided, wherein the process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the pharmacologically active material within the matrix.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18901

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/14 A61K9/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 96 33744 A (PAFRA LTD) 31 October 1996 see page 21 - page 23; example 6 ---	1-12
X	WO 96 03978 A (QUADRANT HOLDINGS CAMBRIDGE ; ROSER BRUCE JOSEPH (GB); COLACO CAMIL) 15 February 1996 see page 8, line 2 - line 17 see page 9, line 12 - line 31 see page 45, line 12 - line 20 see page 50 - page 53; example 2 see figures 2A, 2B ---	1-16
X	EP 0 520 748 A (PAFRA LTD) 30 December 1992 see page 2, line 30 - line 41 see page 4, line 40 - line 58 see page 5, line 18 - line 21 see page 6 - page 7; example 1 ---	1-12, 15
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 June 1998

Date of mailing of the international search report

30/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/18901

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 383 569 A (PAFRA LTD) 22 August 1990 see page 2, line 48 - page 3, line 2 see page 6 - page 7; example 1 ----	1-11,13, 15
P,X	WO 96 32096 A (INHALE THERAPEUTIC SYST ;ELJAMAL MOHAMMED (US); PATTON JOHN S (US)) 17 October 1996 see page 33 - page 37; examples 4,5 ----	1-12,15
X	WO 95 31479 A (INHALE THERAPEUTIC SYSTEMS INC ;PLATZ ROBERT M (US); KIMURA NARINO) 23 November 1995 see page 10, line 25 - page 11, line 9 see page 13 - page 14; example 5 ----	1,3-12, 17-19
X	FRANKS FELIX ET AL: "Materials science and the production of shelf stable biologicals " BIOPHARM, vol. 4, no. 9, 1991, page 40-55 XP002068143 see page 41 - page 43 ----	1-17
A	HATLEY R.: "The effective use of differential scanning calorimetry in the optimization of freeze drying processes and formulations" DEV. BIOL. STAND., vol. 74, 1992, pages 105-122, XP002068144 see page 116 - page 118 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/18901

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9633744	A	31-10-1996	AU 5505696 A EP 0836483 A	18-11-1996 22-04-1998
WO 9603978	A	15-02-1996	AU 688557 B AU 3185195 A BG 101278 A CA 2197982 A CZ 9700476 A EP 0773781 A FI 970867 A JP 10503769 T NO 971688 A NZ 290896 A PL 318898 A SK 27797 A	12-03-1998 04-03-1996 30-12-1997 15-02-1996 13-08-1997 21-05-1997 08-04-1997 07-04-1998 11-04-1997 24-04-1997 21-07-1997 06-08-1997
EP 0520748	A	30-12-1992	AU 659645 B AU 1848692 A CA 2072420 A JP 5293354 A	25-05-1995 07-01-1993 27-12-1992 09-11-1993
EP 0383569	A	22-08-1990	AU 622978 B AU 4924490 A CA 2010058 A DE 69008891 D DE 69008891 T DK 383569 T JP 2265984 A US 5098893 A	30-04-1992 30-08-1990 16-08-1990 23-06-1994 03-11-1994 05-09-1994 30-10-1990 24-03-1992
WO 9632096	A	17-10-1996	AU 5550396 A EP 0820277 A	30-10-1996 28-01-1998
WO 9531479	A	23-11-1995	AU 2514295 A CA 2190502 A EP 0759939 A JP 10500672 T	05-12-1995 23-11-1995 05-03-1997 20-01-1998

**CORRECTED
VERSION*****CORRECTED
VERSION******PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 9/14, 9/72	A3	(11) International Publication Number: WO 98/16205 (43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/18901 (22) International Filing Date: 14 October 1997 (14.10.97) (30) Priority Data: 08/733,225 17 October 1996 (17.10.96) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/733,225 (CIP) Filed on 17 October 1996 (17.10.96) (71) Applicant (for all designated States except US): INHALE THERAPEUTIC SYSTEMS [US/US]; 150 Industrial Road, San Carlos, CA 94070 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FOSTER, Linda, C. [US/US]; Apartment 31, 575 South Rengstorff Avenue, Mountain View, CA 94040 (US). KUO, Mei-chang [US/US]; 1823 Middlefield Road, Palo Alto, CA 94301 (US). BILLINGSLEY, Sheila, R. [US/US]; 665 Kirkland Drive #6, Sunnyvale, CA 94087 (US).	(74) Agents: MORAN, Tom, M.; Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306-2155 (US) et al. (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 3 September 1998 (03.09.98)	
(54) Title: STABLE GLASSY STATE POWDER FORMULATIONS (57) Abstract A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (T_g) and a recommended storage temperature (T_s), wherein the difference between T_g and T_s is at least about 10 °C (i.e. $T_g - T_s$ is greater than 10 °C). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions. A process for producing a powdered dispersible composition is also provided, wherein the process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the pharmacologically active material within the matrix.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						